```
=> fil reg
FILE 'REGISTRY' ENTERED AT 10:43:31 ON 02 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   31 JAN 2003  HIGHEST RN 484598-30-3
DICTIONARY FILE UPDATES:  31 JAN 2003  HIGHEST RN 484598-30-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d his

     (FILE 'HOME' ENTERED AT 09:30:54 ON 02 FEB 2003)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 09:31:30 ON 02 FEB 2003
               E NAALADASE/CN
L1           1 S E3
               E NAALADASE
L2          15 S E3

     FILE 'HCAPLUS' ENTERED AT 09:31:50 ON 02 FEB 2003
L3         521 S L1
L4         528 S L2
L5         121 S NAALADASE
L6         153 S GAMMA(S)GLUTAMYL(S)HYDROLASE OR (ACETYLASPARTYLGLUTAMATE OR A
L7         346 S CARBOXYPEPTIDASE()(G OR G2) OR (GLUTAMATE OR GLUTAMYL OR PSMA
L8         320 S (FOLATE OR FOLIC ACID OR FOLYL)()(CONJUGASE OR HYDROLASE) OR
L9         272 S POLY GAMMA GLUTAMIC ACID ENDOHYDROLASE OR (POLYGLUTAMATE OR P
L10          2 S (PTEROYLPOLY OR PTEROYL POLY)()GAMMA ()(GLUTAMATE OR GLUTAMYL
L11          0 S PTEROLYPOLYGAMMAGLUTAMYL HYDROLASE
L12          0 S PTEROLYPOLYGAMMAGLUTAMIC ACID HYDROLASE
L13          3 S (PTEROYLPOLY OR PTEROYL POLY)(S)GAMMA (S)(GLUTAMATE OR GLUTAM
L14       1070 S L3-L13
               E RETINOPATHY/CT
               E E3+ALL
L15       2582 S E2
L16       1929 S EYE, DISEASE#/CT (L) RETINA?
L17         34 S EYE, DISEASE#/CT (L) ?HYPERTENS?
               E MACULAR DEGENERATION/CT
               E E3+ALL
L18        696 S E2
L19        951 S EYE, DISEASE#/CT (L) MACULA#
L20       1420 S EYE, DISEASE#/CT (L) DEGENER?
               E GLAUCOMA/CT
L21       3023 S E3-E12
               E E3+ALL
L22         69 S E1
               E E3+ALL
```

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
                E GLAUCOMA/CT
                E E4+ALL
L23          2938 S E5,E4+NT
L24          4582 S E6-E9/BI
                E RETINA/CT
                E E3+ALL
L25         13984 S E2
L26         23953 S E1/BI
L27         22680 S RETINAL
L28          4183 S RETINOPATH?
L29          6157 S ?GLAUCOM? OR ?OCULAR?(L)?TENSI?
L30          1236 S MACULA#(L)DEGENER?
                E ANTIGLAUCOMA/CT
L31           976 S E4,E5
                E E4+ALL
L32          1160 S E3-E6/BI
L33            11 S L14 AND L15-L32
                E EYE/CT
L34         55612 S E3-E151
L35         10347 S E152-E170
L36         21003 S E171-E252
L37          3468 S E253-E258,E264
L38          4039 S E274-E279
                E EYE/CT
                E E3+ALL
L39         61384 S E8,E7+NT
                E E25+ALL
L40          1759 S E4-E7/BI
L41         23771 S E3+NT
L42            11 S L14 AND L34-L41
L43            13 S L33,L42
L44             3 S L43 AND ?METAL?
L45             1 S L44 NOT 3/SC,SX
L46            10 S L43 NOT L44
L47             4 S L46 AND BENZEN?/SC,SX,BI
L48             3 S L46 AND BENZO?/SC,SX,BI
L49             5 S L47,L48
L50             6 S L45,L49
L51             5 S L46 NOT L50
                SEL DN AN 3 5
L52             2 S E1-E6
L53             8 S L50,L52
                E SLUSHER B/AU
L54            79 S E3-E8
                E WOZNIAK K/AU
L55           252 S E3-E5,E18-E22
                E GUILFORD/PA,CS
                E GUILF/PA,CS
L56           411 S E4-E39
L57            53 S L56 AND L14
L58             5 S L57 AND L15-L41
L59            68 S L54,L55 AND L14
L60             4 S L59 AND L15-L41
L61             8 S L53,L58,L60
L62             8 S L61 AND L3-L61

     FILE 'REGISTRY' ENTERED AT 10:08:30 ON 02 FEB 2003

     FILE 'HCAPLUS' ENTERED AT 10:08:30 ON 02 FEB 2003
                SET SMARTSELECT ON
L63           SEL L14 1- RN :   13404 TERMS
                SET SMARTSELECT OFF
```

```
     FILE 'REGISTRY' ENTERED AT 10:09:03 ON 02 FEB 2003
L64       13383 S L63

     FILE 'HCAPLUS' ENTERED AT 10:10:02 ON 02 FEB 2003
                SET SMARTSELECT ON
L65           SEL L62 1- RN :     394 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 10:10:03 ON 02 FEB 2003
L66           394 S L65
L67               STR
L68               SCR 2021
L69            50 S L67 AND L68
L70               SCR 1771
L71            30 S L67 AND L70
L72          1429 S L67 AND L70 FUL
                SAV L72 FAY866/A
L73           106 S L72 AND L66
L74           106 S L72 AND L64
L75           106 S L73,L74
L76               STR
L77            12 S L76 SAM SUB=L72
L78               STR L76
L79             4 S L78 SAM SUB=L72
L80           275 S L76 FUL SUB=L72
                SAV L80 FAY866A/A
L81           112 S L78 FUL SUB=L80
                SAV L81 FAY275B/A
                DEL FAY275B/A
                SAV L81 FAY866B/A
L82            59 S L81 NOT L75
L83            24 S L82 AND (C31H32N4O6S OR C42H42N4O5S OR C9H9NO3S2 OR C23H24N2O
L84            14 S L82 AND (C10H13NO2S2 OR C10H11NO5S2 OR C9H9NO3S2 OR C23H24NO5
L85             3 S L82 AND (C23H25NO5S2 OR C44H42N4O5S2 OR C39H41N5O5S)
L86            36 S L83-L85
L87            23 S L82 NOT L86
L88           129 S L75,L87
                SAV L88 FAY866C/A

     FILE 'HCAOLD' ENTERED AT 10:37:04 ON 02 FEB 2003
L89             2 S L88
                SEL AN
                EDIT /AN /OREF

     FILE 'HCAPLUS' ENTERED AT 10:37:29 ON 02 FEB 2003
L90             4 S E1-E2
L91             2 S L90 NOT (PERIARD ? OR VOSS ?)/AU
L92            47 S L88
L93             5 S L92 AND L62
L94             3 S L62 NOT L93
L95             8 S L62,L93,L94
L96             6 S L92 AND L14
L97             7 S L92 AND L15-L32,L34-L41
L98             8 S L96,L97
L99            11 S L98,L95
L100            7 S L99 AND (PD<=20000530 OR PRD<=20000530 OR AD<=20000530)
L101            4 S L99 NOT L100
L102            7 S L100 AND L3-L62,L90-L101
L103            4 S L101 AND L3-L62,L90-L102

     FILE 'REGISTRY' ENTERED AT 10:43:31 ON 02 FEB 2003

=> d l1 ide can
```

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS
RN 9074-87-7 REGISTRY
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)
OTHER NAMES:
CN .gamma.-Glutamyl hydrolase
CN Acetylaspartylglutamate dipeptidase
CN Carboxypeptidase G
CN Carboxypeptidase G 2
CN Conjugase
CN E.C. 3.4.12.10
CN E.C. 3.4.17.11
CN E.C. 3.4.17.21
CN E.C. 3.4.19.9
CN E.C. 3.4.22.12
CN Folate conjugase
CN Folate hydrolase
CN Folic acid conjugase
CN Folyl conjugase
CN Folylpoly-.gamma.-glutamate carboxypeptidase
CN Folylpolyglutamate hydrolase
CN Glutamate carboxypeptidase
CN Glutamate carboxypeptidase II
CN Glutamyl carboxypeptidase
CN N-Acetylated-.alpha.-linked acidic dipeptidase
CN N-acetylated-.alpha.-linked-amino dipeptidase
CN N-Pteroyl-L-glutamate hydrolase
CN **NAALADase**
CN Poly(.gamma.-glutamic acid) endohydrolase
CN Polyglutamate hydrolase
CN Prostate-specific membrane antigen
CN PSMA carboxypeptidase
CN Pteroyl-.gamma.-glutamyl carboxypeptidase
CN Pteroylpoly-.gamma.-glutamate hydrolase
CN Pteroylpoly-.gamma.-glutamyl hydrolase
CN Pteroylpolygammaglutamyl hydrolase
CN Pteroylpolyglutamate hydrolase
CN Pteroylpolyglutamic acid hydrolase
DR 55326-32-4, 61584-57-4, 37279-02-0, 111070-04-3
MF Unspecified
CI MAN
LC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CIN, DDFU, DRUGU, EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
461 REFERENCES IN FILE CA (1962 TO DATE)
33 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
462 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:67363

REFERENCE 2: 138:38068

REFERENCE 3: 138:24015

REFERENCE 4: 138:13959

REFERENCE 5: 138:13048

REFERENCE 6: 137:380049

REFERENCE 7: 137:367451

REFERENCE 8: 137:365725

REFERENCE 9: 137:362990

REFERENCE 10: 137:351659

=> d sta que l81
L67 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 2
NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE
L70 SCR 1771
L72 1429 SEA FILE=REGISTRY SSS FUL L67 AND L70
L76 STR



VAR G1=6/10/13/16
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

L78 STR



VAR G1=6/10/13/16
REP G2=(2-2) C
REP G3=(0-2) C
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L80 275 SEA FILE=REGISTRY SUB=L72 SSS FUL L76
L81 112 SEA FILE=REGISTRY SUB=L80 SSS FUL L78

100.0% PROCESSED 275 ITERATIONS 112 ANSWERS
SEARCH TIME: 00.00.01

=> fil hcaold
FILE 'HCAOLD' ENTERED AT 10:44:46 ON 02 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

PRE-1967 CHEMICAL ABSTRACTS FILE WITH HOUR-BASED PRICING
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all hitstr tot l89

L89 ANSWER 1 OF 2 HCAOLD COPYRIGHT 2003 ACS
AN CA58:3359g CAOLD
TI products from HCHO and o-mercaptomethylbenzoic acid
AU Schlatter, Maurice J.
PA Chevron Research Co.
DT Patent

	PATENT NO.	KIND	DATE
PI	US 3053890		1962

IT **38335-14-7** 90536-44-0
IT **38335-14-7**
RN 38335-14-7 HCAOLD
CN Benzoic acid, 2-(mercaptomethyl)- (9CI) (CA INDEX NAME)



L89 ANSWER 2 OF 2 HCAOLD COPYRIGHT 2003 ACS
AN CA53:20529f CAOLD
TI aminopterin for psoriasis
AU Rees, Rees B.; Bennett, J. H.
IT 70-49-5 96-27-5 758-08-7 760-30-5 763-35-9 1190-73-4
3375-50-6 4542-46-5 6986-60-3 13839-15-1 18889-18-4 19788-48-8
20292-02-8 20938-74-3 21115-85-5 24517-45-1 24687-42-1 32810-20-1
35331-24-9 **39088-65-8** 42302-16-9 49594-30-1 51621-19-3
54010-24-1 69753-45-3 88512-15-6 88512-26-9 89166-53-0 91007-96-4
92204-20-1 92204-26-7 98025-55-9 98137-55-4 98278-38-7 100368-00-1
IT **39088-65-8**
RN 39088-65-8 HCAOLD
CN Benzoic acid, 4-(mercaptomethyl)- (9CI) (CA INDEX NAME)



=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:44:57 ON 02 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 31 Jan 2003 (20030131/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot l91

L91 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 1963:20561 HCAPLUS
DN 58:20561
OREF 58:**3359g-h**
TI Products from formaldehyde and o-mercaptomethylbenzoic acid
IN Schlatter, Maurice J.
PA California Research Corp.
SO 4 pp.
DT Patent
LA Unavailable
NCL 260516000
CC 35 (Noncondensed Aromatic Compounds)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3053890		19620911	US	19600331

AB Hydroxymethyl o-carboxybenzyl sulfide (I), m. 133.6-4.2.degree. was prepd. from a mixt. of 7.38 g. aq. HCHO (36.6%) and 5.05 g. o-mercaptomethylbenzoic acid (II) in 60 ml. EtOH. II (10 g.) in 20 g. aq. HCHO (36.6%) heated 1 hr. at 80-90.degree. and cooled gave 3.41 g. bis(o-carboxybenzylthio)methane (III), m. 199.6-201.0.degree. (alc.). III was also obtained by heating I at 165.degree.. The hexamethylene salt of III was prepd. in H2O and polymerized by heating in an oil bath at 260.degree. for 30 min. under N and then for 2-4 hrs. while gradually reducing the pressure to 1 mm. The polymer is a useful component of surface coatings.
IT Formaldehyde, homopolymer
(reaction products of, with .alpha.-mercapto-o-toluic acid)
IT o-Toluic acid, .alpha.,.alpha.'-(methylenedithio)di-, 1,6-hexanediamine salt
IT 90536-44-0, o-Toluic acid, .alpha.-[(hydroxymethyl)thio]-
(prepn. of)
IT 38335-14-7, o-Toluic acid, .alpha.-mercapto-
(reaction products with formaldehyde)

L91 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS
AN 1959:114400 HCAPLUS
DN 53:114400
OREF 53:**20529f-h**
TI Further observations on aminopterin for psoriasis
AU Rees, Rees B.; Bennett, James H.
CS Univ. of California, San Francisco
SO J. Invest. Dermatol. (1959), 32, 61-6
DT Journal
LA Unavailable
CC 11H (Biological Chemistry: Pharmacology)
AB Improvement or clearing of psoriatic lesions occurred in 82% of psoriatic patients given a total of not more than 6 mg. aminopterin over a period of several days. Toxic symptoms developed in 21% of the patients treated (in 28% of those whose response was excellent). Mild toxic symptoms were observed in 39% of a test group given over 100 mg. during a period of 1-5 years. Daraprim in doses of 25 mg. daily for 1 month was without benefit or significant toxic effect; similar neg. results were obtained with purinethol (6-mercaptopurine) in doses of 50 mg. 4 times daily for 6 days.

=> d l102 all hitstr tot

L102 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:886142 HCAPLUS

DN 136:15255
TI **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**
IN **Slusher, Barbara S.; Wozniak, Krystyna**
PA **Guilford Pharmaceuticals Inc., USA**
SO PCT Int. Appl., 196 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07F009-02
CC 1-12 (Pharmacology)
Section cross-reference(s): 29, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001092274	A2	20011206	WO 2001-US17288	20010530 <--
	WO 2001092274	A3	20020530		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-207320P P 20000530 <--
OS MARPAT 136:15255
AB The invention discloses pharmaceutical compns. and methods for treating a **retinal** disorder or **glaucoma** using **NAALADase** inhibitors.
ST **NAALADase** inhibitor prepn **retinal** disorder **glaucoma**
IT **Antiglaucoma agents**
Drug delivery systems
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT Resolution (separation)
(chromatog.; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT **Eye, disease**
(**diabetic retinopathy; NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT **Eye, disease**
(**macula, senile degeneration; NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT **Metals**, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**metal**-binding group-contg. acids; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT Acids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**metal**-binding group-contg.; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT **Eye, disease**
(**retinopathy; NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT **378241-97-5P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT 2417-72-3P **377731-26-5P 377731-28-7P 378241-94-2P 378242-00-3P 378242-07-0P 378242-12-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT 89-73-6 89-73-6D, enantiomers 99-31-0 99-31-0D, enantiomers 528-44-9, 1,2,4-Benzenetricarboxylic acid 528-44-9D, 1,2,4-Benzenetricarboxylic acid, enantiomers 554-95-0, 1,3,5-Benzenetricarboxylic acid 554-95-0D, 1,3,5-Benzenetricarboxylic acid, enantiomers 586-35-6 586-35-6D, enantiomers 610-29-7 610-29-7D, enantiomers 618-83-7 618-83-7D, enantiomers 618-88-2 618-88-2D, enantiomers 636-46-4 636-46-4D, enantiomers 4315-09-7 4315-09-7D, enantiomers 6344-50-9 6344-50-9D, enantiomers 10312-55-7 10312-55-7D, enantiomers 19089-60-2 19089-60-2D, enantiomers 21615-52-1 21615-52-1D, enantiomers 22326-31-4 22326-31-4D, enantiomers 25062-54-8 25062-54-8D, enantiomers **28162-88-1 28162-88-1D**, enantiomers **38335-14-7** 52137-56-1 52137-56-1D, enantiomers 76784-92-4 76784-92-4D, enantiomers 143193-46-8 143193-46-8D, enantiomers 173039-10-6 173039-10-6D, enantiomers 173039-11-7 173039-11-7D, enantiomers 197630-75-4 197630-75-4D, enantiomers 197630-78-7 197630-78-7D, enantiomers 197630-80-1 197630-80-1D, enantiomers 197630-81-2 197630-81-2D, enantiomers 200123-75-7 200123-75-7D, enantiomers 200698-17-5 200698-17-5D, enantiomers 200698-19-7 200698-19-7D, enantiomers 200698-20-0 200698-20-0D, enantiomers 200698-21-1 200698-21-1D, enantiomers 200698-22-2 200698-22-2D, enantiomers 200698-23-3 200698-23-3D, enantiomers 200698-24-4 200698-24-4D, enantiomers 200698-25-5 200698-25-5D, enantiomers 200698-26-6 200698-26-6D, enantiomers 200717-37-9 200717-37-9D, enantiomers 201041-22-7 201041-22-7D, enantiomers 209470-89-3 209470-89-3D, enantiomers 254737-18-3 254737-18-3D, enantiomers 254737-19-4 254737-19-4D, enantiomers 254737-20-7 254737-20-7D, enantiomers 254737-21-8 254737-21-8D, enantiomers 254737-22-9 254737-22-9D, enantiomers 254737-23-0 254737-23-0D, enantiomers 254737-24-1 254737-24-1D, enantiomers 254737-25-2 254737-25-2D, enantiomers 254737-28-5 254737-28-5D, enantiomers 254737-29-6 254737-29-6D, enantiomers 254737-30-9 254737-30-9D, enantiomers 254737-31-0 254737-31-0D, enantiomers 254737-32-1 254737-32-1D, enantiomers 254737-33-2 254737-33-2D, enantiomers 254737-34-3 254737-34-3D, enantiomers 254737-35-4 254737-35-4D, enantiomers 254737-36-5 254737-36-5D, enantiomers 267410-70-8 267410-70-8D, enantiomers 272128-61-7 272128-61-7D, enantiomers 272128-62-8 272128-62-8D, enantiomers 293761-62-3 293761-62-3D, enantiomers 303996-38-5 303996-38-5D, enantiomers 318480-81-8 320417-29-6 320417-29-6D, enantiomers 377081-80-6 377081-80-6D, enantiomers 377081-81-7 377081-81-7D, enantiomers 377081-82-8 377081-82-8D, enantiomers **377081-83-9 377081-83-9D**, enantiomers 377081-84-0 377081-84-0D, enantiomers 377081-85-1 377081-85-1D, enantiomers 377081-86-2 377081-86-2D, enantiomers 377081-87-3 377081-87-3D, enantiomers 377081-88-4 377081-88-4D, enantiomers 377081-89-5 377081-89-5D, enantiomers **377081-90-8 377081-90-8D**, enantiomers **377081-91-9 377081-91-9D**, enantiomers 377081-92-0

377081-92-0D, enantiomers **377081-93-1 377081-93-1D,**
enantiomers 377081-94-2 377081-94-2D, enantiomers 377081-95-3
377081-95-3D, enantiomers 377081-96-4 377081-96-4D, enantiomers
377081-97-5 377081-97-5D, enantiomers 377081-98-6
377081-98-6D, enantiomers 377081-99-7 377081-99-7D, enantiomers
377082-00-3 377082-00-3D, enantiomers 377082-01-4 377082-01-4D,
enantiomers **378242-00-3D,** enantiomers **378242-07-0D,**
enantiomers **378242-12-7D,** enantiomers 378242-18-3
378242-19-4 378242-20-7 378242-21-8 **378242-22-9**
378242-23-0 378242-24-1 378242-25-2 **378242-26-3**
378242-27-4 378242-28-5 378242-29-6 **378242-30-9**
378242-31-0 378242-32-1 378242-33-2 378242-34-3 378242-35-4
378242-36-5 378242-37-6 378242-38-7 378242-39-8 378242-40-1
378242-41-2 378242-43-4 **378242-44-5** 378242-45-6
378242-46-7 378242-47-8 378242-48-9
378242-49-0 378242-50-3 378242-51-4
378242-52-5 378242-53-6 378242-54-7
378242-55-8 378242-56-9 378242-57-0
378242-58-1 378242-59-2 378242-60-5 378242-61-6
378242-62-7 378242-63-8 **378242-64-9**
378242-66-1 378242-67-2 378242-67-2D,
enantiomers **378242-68-3 378242-68-3D,** enantiomers
378242-69-4 378242-69-4D, enantiomers
378242-70-7 378242-70-7D, enantiomers
378242-71-8 378242-71-8D, enantiomers
378242-72-9 378242-72-9D, enantiomers
378242-73-0 378242-73-0D, enantiomers
378242-74-1 378242-74-1D, enantiomers
378242-75-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(**NAALADase** inhibitors for treating **retinal**
disorders and **glaucoma**)

IT **378242-75-2D,** enantiomers **378242-76-3**
378242-76-3D, enantiomers **378242-77-4**
378242-77-4D, enantiomers **378242-78-5**
378242-78-5D, enantiomers **378242-79-6**
378242-79-6D, enantiomers **378242-80-9**
378242-80-9D, enantiomers **378242-81-0**
378242-81-0D, enantiomers **378242-82-1**
378242-82-1D, enantiomers **378242-83-2**
378242-83-2D, enantiomers **378242-84-3**
378242-84-3D, enantiomers **378242-85-4**
378242-85-4D, enantiomers **378242-86-5**
378242-86-5D, enantiomers **378242-88-7**
378242-88-7D, enantiomers **378242-89-8**
378242-89-8D, enantiomers **378242-90-1**
378242-90-1D, enantiomers **378242-91-2**
378242-91-2D, enantiomers **378242-92-3**
378242-92-3D, enantiomers **378242-93-4**
378242-93-4D, enantiomers **378242-94-5**
378242-94-5D, enantiomers **378242-95-6**
378242-95-6D, enantiomers **378242-96-7**
378242-96-7D, enantiomers **378242-97-8**
378242-97-8D, enantiomers **378242-98-9**
378242-98-9D, enantiomers **378242-99-0**
378242-99-0D, enantiomers **378243-00-6**
378243-00-6D, enantiomers **378243-01-7**
378243-01-7D, enantiomers 378243-04-0 378243-04-0D,
enantiomers 378243-05-1 378243-05-1D, enantiomers 378243-06-2
378243-06-2D, enantiomers 378243-07-3 378243-07-3D, enantiomers
378243-08-4 378243-08-4D, enantiomers 378243-09-5 378243-09-5D,
enantiomers 378243-10-8 378243-10-8D, enantiomers 378243-11-9

378243-11-9D, enantiomers 378243-12-0 378243-12-0D, enantiomers
378243-13-1 378243-13-1D, enantiomers 378243-14-2 378243-14-2D,
enantiomers 378243-15-3 378243-15-3D, enantiomers 378243-16-4
378243-16-4D, enantiomers 378243-17-5 378243-17-5D, enantiomers
378243-18-6 378243-18-6D, enantiomers 378243-19-7 378243-19-7D,
enantiomers 378243-20-0 378243-20-0D, enantiomers 378243-21-1
378243-21-1D, enantiomers 378243-22-2 378243-22-2D, enantiomers
378243-23-3 378243-23-3D, enantiomers 378243-24-4 378243-24-4D,
enantiomers 378243-25-5 378243-25-5D, enantiomers 378243-26-6
378243-26-6D, enantiomers 378243-27-7 378243-27-7D, enantiomers
378243-28-8 378243-28-8D, enantiomers 378243-29-9 378243-29-9D,
enantiomers 378243-30-2 378243-30-2D, enantiomers 378243-31-3
378243-32-4 378243-33-5 378243-34-6 378243-35-7 378243-36-8
378243-37-9D, enantiomers 378243-40-4 378243-40-4D, enantiomers
378243-41-5 378243-41-5D, enantiomers 378243-42-6 378243-42-6D,
enantiomers 378243-43-7 378243-43-7D, enantiomers 378243-44-8
378243-44-8D, enantiomers 378243-45-9 378243-45-9D, enantiomers
378243-46-0 378243-46-0D, enantiomers 378243-47-1 378243-47-1D,
enantiomers 378243-48-2 378243-48-2D, enantiomers 378243-49-3
378243-49-3D, enantiomers 378243-50-6 378243-50-6D, enantiomers
378243-51-7 378243-51-7D, enantiomers 378243-52-8 378243-52-8D,
enantiomers 378243-53-9 378243-53-9D, enantiomers 378243-54-0
378243-54-0D, enantiomers 378243-55-1 378243-55-1D, enantiomers
378243-57-3 378243-57-3D, enantiomers 378243-58-4 378243-58-4D,
enantiomers 378243-59-5 378243-59-5D, enantiomers 378243-60-8
378243-60-8D, enantiomers 378243-61-9 378243-61-9D, enantiomers
378243-63-1 **378243-64-2 378243-65-3**
378243-66-4 378243-67-5 378243-68-6
378243-69-7 378243-70-0 378243-71-1
378243-72-2 378243-73-3 378243-75-5
378243-76-6 378243-77-7 378243-78-8
378243-79-9 **378243-80-2 378243-81-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT **378241-98-6P 378241-99-7P**
RL: PUR (Purification or recovery); PREP (Preparation)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT 185051-07-4P 220464-68-6P 377082-02-5P 377082-03-6P 377082-04-7P
377082-05-8P 377082-06-9P 377731-27-6P 377731-29-8P 377731-30-1P
377731-31-2P 377731-32-3P 377731-33-4P 377731-34-5P 378241-95-3P
378242-01-4P 378242-02-5P 378242-03-6P 378242-04-7P 378242-05-8P
378242-06-9P 378242-08-1P 378242-09-2P 378242-10-5P
378242-11-6P 378242-13-8P 378242-15-0P 378242-16-1P 378242-17-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT 99-06-9, reactions 122-52-1, Triethyl phosphite 358-23-6, Triflic anhydride 507-09-5, Thioacetic acid, reactions 1003-42-5 2687-43-6, O-Benzylhydroxylamine hydrochloride 4105-93-5 4334-87-6 5985-24-0 6967-82-4 7486-35-3, Tributyl(vinyl)tin 10387-40-3, Potassium thioacetate 16308-65-9 25487-66-5, 3-Carboxyphenylboronic acid 29547-04-4 91367-05-4 156750-11-7 164014-40-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **378241-97-5P**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
RN 378241-97-5 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(2-mercaptoethyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



IT **377731-26-5P 377731-28-7P 378241-94-2P**
378242-00-3P 378242-07-0P 378242-12-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
RN 377731-26-5 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-2-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 377731-28-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378241-94-2 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 378242-00-3 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-07-0 HCAPLUS
CN Benzoic acid, 2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-12-7 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 4-(mercaptomethyl)- (9CI) (CA INDEX NAME)



IT **28162-88-1 28162-88-1D**, enantiomers **38335-14-7**
377081-83-9 377081-83-9D, enantiomers
377081-90-8 377081-90-8D, enantiomers
377081-91-9 377081-91-9D, enantiomers
377081-93-1 377081-93-1D, enantiomers
377081-97-5 377081-97-5D, enantiomers
378242-00-3D, enantiomers **378242-07-0D**, enantiomers
378242-12-7D, enantiomers **378242-22-9**
378242-23-0 378242-26-3 378242-27-4
378242-30-9 378242-44-5 378242-46-7
378242-47-8 378242-48-9 378242-49-0
378242-50-3 378242-51-4 378242-52-5
378242-53-6 378242-55-8 378242-56-9
378242-58-1 378242-62-7 378242-64-9
378242-66-1 378242-67-2 378242-67-2D,

enantiomers **378242-68-3 378242-68-3D**, enantiomers
378242-69-4 378242-69-4D, enantiomers
378242-70-7 378242-70-7D, enantiomers
378242-71-8 378242-71-8D, enantiomers
378242-72-9 378242-72-9D, enantiomers
378242-73-0 378242-73-0D, enantiomers
378242-74-1 378242-74-1D, enantiomers
378242-75-2 378242-75-2D, enantiomers
378242-76-3 378242-76-3D, enantiomers
378242-77-4 378242-77-4D, enantiomers
378242-78-5 378242-78-5D, enantiomers
378242-79-6 378242-79-6D, enantiomers
378242-80-9 378242-80-9D, enantiomers
378242-81-0 378242-81-0D, enantiomers
378242-82-1 378242-82-1D, enantiomers
378242-83-2 378242-83-2D, enantiomers
378242-84-3 378242-84-3D, enantiomers
378242-85-4 378242-85-4D, enantiomers
378242-86-5 378242-86-5D, enantiomers
378242-88-7 378242-88-7D, enantiomers
378242-89-8 378242-89-8D, enantiomers
378242-90-1 378242-90-1D, enantiomers
378242-91-2 378242-91-2D, enantiomers
378242-92-3 378242-92-3D, enantiomers
378242-93-4 378242-93-4D, enantiomers
378242-94-5 378242-94-5D, enantiomers
378242-95-6 378242-95-6D, enantiomers
378242-96-7 378242-96-7D, enantiomers
378242-97-8 378242-97-8D, enantiomers
378242-98-9 378242-98-9D, enantiomers
378242-99-0 378242-99-0D, enantiomers
378243-00-6 378243-00-6D, enantiomers
378243-01-7 378243-01-7D, enantiomers
378243-64-2 378243-65-3 378243-66-4
378243-67-5 378243-68-6 378243-69-7
378243-70-0 378243-71-1 378243-72-2
378243-73-3 378243-75-5 378243-76-6
378243-77-7 378243-78-8 378243-80-2
378243-81-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)

RN 28162-88-1 HCAPLUS
CN Benzoic acid, 3-(mercaptomethyl)- (9CI) (CA INDEX NAME)

RN 28162-88-1 HCAPLUS
CN Benzoic acid, 3-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 38335-14-7 HCAPLUS
CN Benzoic acid, 2-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-83-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-83-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-90-8 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 377081-90-8 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 377081-91-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethoxy)- (9CI) (CA INDEX NAME)



RN 377081-91-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethoxy)- (9CI) (CA INDEX NAME)



RN 377081-93-1 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-93-1 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-97-5 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-97-5 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-00-3 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-07-0 HCAPLUS
CN Benzoic acid, 2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-12-7 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 4-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378242-22-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-23-0 HCAPLUS
CN Benzenepropanoic acid, 4-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA

INDEX NAME)



RN 378242-26-3 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-carboxy-5-mercaptopentyl)- (9CI) (CA INDEX NAME)



RN 378242-27-4 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-4-fluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-30-9 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-44-5 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-methoxy- (9CI) (CA INDEX NAME)



RN 378242-46-7 HCAPLUS
CN Benzoic acid, 2-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-47-8 HCAPLUS
CN Benzoic acid, 4-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-48-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-2-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-49-0 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-4-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-50-3 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-chloro- (9CI) (CA INDEX NAME)



RN 378242-51-4 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-fluoro- (9CI) (CA INDEX NAME)



RN 378242-52-5 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-2-fluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-53-6 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 378242-55-8 HCAPLUS
CN Benzenepropanoic acid, 2-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-56-9 HCAPLUS
CN Benzenepropanoic acid, 4-carboxy-2,3,5,6-tetrafluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-58-1 HCAPLUS
CN Benzoic acid, 3-[(1-carboxy-4-mercaptobutyl)thio]- (9CI) (CA INDEX NAME)



RN 378242-62-7 HCAPLUS
CN Benzenepropanoic acid, 3-bromo-5-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-64-9 HCAPLUS
CN Benzenepropanoic acid, 3-bromo-4-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-66-1 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-nitro- (9CI) (CA INDEX NAME)



RN 378242-67-2 HCAPLUS
CN Benzoic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-67-2 HCAPLUS
CN Benzoic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-68-3 HCAPLUS
CN Benzoic acid, 5-hydroxy-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-68-3 HCAPLUS
CN Benzoic acid, 5-hydroxy-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-69-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-69-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-70-7 HCAPLUS
CN Benzoic acid, 5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-70-7 HCAPLUS
CN Benzoic acid, 5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-71-8 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-71-8 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-72-9 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-72-9 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-73-0 HCAPLUS
CN Benzoic acid, 5-[(2-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-73-0 HCAPLUS
CN Benzoic acid, 5-[(2-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-74-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-74-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-75-2 HCAPLUS
CN Benzoic acid, 2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-75-2 HCAPLUS
CN Benzoic acid, 2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-76-3 HCAPLUS
CN Benzoic acid, 2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX

NAME)



RN 378242-76-3 HCAPLUS
CN Benzoic acid, 2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-77-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-77-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-78-5 HCAPLUS
CN Benzoic acid, 2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-78-5 HCAPLUS
CN Benzoic acid, 2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-79-6 HCAPLUS
CN Benzoic acid, 2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-79-6 HCAPLUS
CN Benzoic acid, 2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-80-9 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-phenoxy- (9CI) (CA INDEX NAME)



RN 378242-80-9 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-phenoxy- (9CI) (CA INDEX NAME)



RN 378242-81-0 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 378242-81-0 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 378242-82-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylthio)- (9CI) (CA INDEX NAME)



RN 378242-82-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylthio)- (9CI) (CA INDEX NAME)



RN 378242-83-2 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 5'-(1,1-dimethylethyl)-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-83-2 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 5'-(1,1-dimethylethyl)-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-84-3 HCAPLUS
CN [1,1'-Biphenyl]-2,4'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-84-3 HCAPLUS
CN [1,1'-Biphenyl]-2,4'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)





RN 378242-85-4 HCAPLUS
CN Benzoic acid, 2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-85-4 HCAPLUS
CN Benzoic acid, 2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)-
(9CI) (CA INDEX NAME)



RN 378242-86-5 HCAPLUS
CN Benzoic acid, 4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-2-methoxy-
(9CI) (CA INDEX NAME)



RN 378242-86-5 HCAPLUS
CN Benzoic acid, 4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-2-methoxy-
(9CI) (CA INDEX NAME)



RN 378242-88-7 HCAPLUS
CN Benzoic acid, 2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-
(9CI) (CA INDEX NAME)



RN 378242-88-7 HCAPLUS
CN Benzoic acid, 2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-89-8 HCAPLUS
CN Benzoic acid, 2-bromo-4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-89-8 HCAPLUS
CN Benzoic acid, 2-bromo-4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-90-1 HCAPLUS
CN Benzoic acid, 2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-90-1 HCAPLUS
CN Benzoic acid, 2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-91-2 HCAPLUS
CN Benzoic acid, 2-([1,1'-biphenyl]-2-ylmethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-91-2 HCAPLUS
CN Benzoic acid, 2-([1,1'-biphenyl]-2-ylmethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-92-3 HCAPLUS
CN Benzoic acid, 2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-92-3 HCAPLUS
CN Benzoic acid, 2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-93-4 HCAPLUS
CN Benzoic acid, 2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)-

(9CI) (CA INDEX NAME)



RN 378242-93-4 HCAPLUS
CN Benzoic acid, 2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-94-5 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-94-5 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-95-6 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-95-6 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-96-7 HCAPLUS
CN Benzoic acid, 2-bromo-5-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-96-7 HCAPLUS
CN Benzoic acid, 2-bromo-5-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-97-8 HCAPLUS
CN Benzoic acid, 2-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 378242-97-8 HCAPLUS
CN Benzoic acid, 2-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 378242-98-9 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-98-9 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-99-0 HCAPLUS
CN Benzoic acid, 2-bromo-5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378242-99-0 HCAPLUS
CN Benzoic acid, 2-bromo-5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378243-00-6 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378243-00-6 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378243-01-7 HCAPLUS
CN Benzoic acid, 4-bromo-3-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378243-01-7 HCAPLUS
CN Benzoic acid, 4-bromo-3-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378243-64-2 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)-2-nitro- (9CI)

(CA INDEX NAME)



RN 378243-65-3 HCAPLUS
CN [1,1'-Biphenyl]-3-propanoic acid, 3'-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-66-4 HCAPLUS
CN Benzenepropanoic acid, 2-bromo-5-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-67-5 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 378243-68-6 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 378243-69-7 HCAPLUS
CN [1,1'-Biphenyl]-2-propanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-70-0 HCAPLUS
CN [1,1'-Biphenyl]-2-propanoic acid, 6-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-71-1 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 2-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-72-2 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-methoxy-
(9CI) (CA INDEX NAME)



RN 378243-73-3 HCAPLUS
CN [1,1'-Biphenyl]-3-propanoic acid, 2'-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-75-5 HCAPLUS
CN Benzenepropanoic acid, 3-(2-carboxyphenoxy)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-76-6 HCAPLUS
CN Benzenepropanoic acid, 4-(2-carboxyphenoxy)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-77-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptobutyl)- (9CI) (CA INDEX NAME)



RN 378243-78-8 HCAPLUS

CN [1,1'-Biphenyl]-4-propanoic acid, 2'-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-80-2 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-phenoxy- (9CI) (CA INDEX NAME)



RN 378243-81-3 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptobutyl)- (9CI) (CA INDEX NAME)



IT **378241-98-6P 378241-99-7P**
RL: PUR (Purification or recovery); PREP (Preparation)
(**NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
RN 378241-98-6 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(2-mercaptoethyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

RN 378241-99-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



IT **378242-06-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; **NAALADase** inhibitors for treating **retinal** disorders and **glaucoma**)
RN 378242-06-9 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 3-(2-mercaptoethyl)-, 2-methyl ester (9CI) (CA INDEX NAME)



L102 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:886141 HCAPLUS
DN 136:15254
TI **Benzenedicarboxylic** acid derivatives as **NAALADase** inhibitors, their preparation, and their therapeutic use
IN Jackson, Paul F.; Tsukamoto, Takashi; **Slusher, Barbara S.**; Wang, Eric
PA **Guilford Pharmaceuticals Inc., USA**
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07F009-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 9, 29, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001092273	A2	20011206	WO 2001-US17309	20010529 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002019430	A1	20020214	US 2001-866758	20010530 <--
US 6452044	B2	20020917		
PRAI US 2000-207402P	P	20000530 <--		

OS MARPAT 136:15254
AB The invention discloses **benzenedicarboxylic** acid deriv. compds.;

pharmaceutical compns., diagnostic methods, and diagnostic kits that include these compds.; and methods of using these compds. for inhibiting **NAALADase** enzyme activity, detecting diseases where **NAALADase** levels are altered, effecting neuronal activity, effecting TGF-.beta. activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, and **glaucoma**.

ST **benzenedicarboxylate** deriv prepn **NAALADase** inhibitor therapeutic diagnostic

IT Nervous system
(amyotrophic lateral sclerosis; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Alcoholism
Analgesics
Angiogenesis inhibitors
Anti-ischemic agents
Antidiabetic agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Anxiolytics
Cognition enhancers
Diagnosis
Drug delivery systems
Drug dependence
Nervous system agents
Schizophrenia
Test kits
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Antitumor agents
(brain; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Mental disorder
(compulsive disorder; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Nerve, disease
(degeneration; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Nerve, disease
(demyelination; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Nerve, disease
(diabetic neuropathy; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Nervous system
Prostate gland
(disease; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Brain, neoplasm
Kidney, neoplasm
Testis, neoplasm
(inhibitors; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Brain, disease
Nerve, disease
Spinal cord
(injury; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Diabetes mellitus
(insulin-dependent, peripheral neuropathy or neuropathic pain from; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT Antitumor agents
(kidney; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Prostate gland
(neoplasm, inhibitors; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Regeneration, animal
(nerve; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Nerve, disease
(neuropathy, and neuropathic pain; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Cytoprotective agents
(neuroprotectants; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Diabetes mellitus
(non-insulin-dependent, peripheral neuropathy or neuropathic pain from; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Chemicals
Human immunodeficiency virus
(peripheral neuropathy or neuropathic pain from; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Vitamins
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(peripheral neuropathy or neuropathic pain from; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Nerve, disease
(peripheral neuropathy; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Antitumor agents
(prostate gland; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Nerve
(regeneration; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Brain, disease
(stroke; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Antitumor agents
(testis; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Brain, disease
(trauma; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.-; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.1-; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.2-; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 64-17-5, Ethanol, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(alc. dependence; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

IT 50-36-2, Cocaine 54-11-5, Nicotine
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 25062-54-8P **377081-83-9P** 377081-92-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 57-27-2, Morphine, biological studies 99-31-0 528-44-9, 1,2,4-**Benzenetricarboxylic** acid 554-95-0, 1,3,5-**Benzenetricarboxylic** acid 586-35-6 610-29-7 618-83-7
618-88-2 636-46-4 4315-09-7 6344-50-9 10312-55-7 19089-60-2
21615-52-1 22326-31-4 52137-56-1 76784-92-4 143193-46-8
173039-10-6 200123-75-7 200698-26-6 209470-89-3 254737-18-3
267410-70-8 272128-61-7 272128-62-8 293761-62-3 377081-80-6
377081-81-7 377081-82-8 377081-84-0 377081-85-1 377081-86-2
377081-87-3 377081-88-4 377081-89-5 **377081-90-8**
377081-91-9 377081-93-1 377081-94-2 377081-95-3
377081-96-4 **377081-97-5** 377081-98-6 377081-99-7
377082-00-3 377082-01-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 56-86-0, L-Glutamic acid, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutamate abnormalities; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 185051-07-4P 377082-02-5P 377082-03-6P 377082-04-7P 377082-05-8P
377082-06-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT 122-52-1, Triethylphosphite 358-23-6, Triflic anhydride 507-09-5, Thioacetic acid, reactions 2687-43-6, O-Benzylhydroxylamine hydrochloride 4105-93-5 5985-24-0 156750-11-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; **benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **377081-83-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)
RN 377081-83-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



IT **377081-90-8 377081-91-9 377081-93-1**
377081-97-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**benzenedicarboxylic** acid derivs. as **NAALADase** inhibitors, prepn., and therapeutic use)

RN 377081-90-8 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 377081-91-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethoxy)- (9CI) (CA INDEX NAME)



RN 377081-93-1 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-97-5 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



L102 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:885736 HCAPLUS
DN 136:15243
TI **NAALADase** inhibitors for treating amyotrophic lateral sclerosis
IN **Slusher, Barbara S.; Wozniak, Krystyna**
PA **Guilford Pharmaceuticals Inc., USA**
SO PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
CC 1-11 (Pharmacology)
Section cross-reference(s): 29, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001091738	A2	20011206	WO 2001-US17325	20010530 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002013295	A1	20020131	US 2001-866729	20010530 <--
PRAI US 2000-207319P	P	20000530 <--		

OS MARPAT 136:15243
AB The invention discloses pharmaceutical compns. and methods for treating amyotrophic lateral sclerosis using **NAALADase** inhibitors.
ST **NAALADase** inhibitor prepn amyotrophic lateral sclerosis
IT Drug delivery systems
Nervous system agents
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT Nervous system
(amyotrophic lateral sclerosis; **NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT Metals, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(metal-binding group-contg. acids; **NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT Acids, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(metal-binding group-contg.; **NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT **9074-87-7, Naaladase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT **377731-26-5P 377731-28-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)
IT 99-31-0 99-31-0D, enantiomers 528-44-9, 1,2,4-Benzenetricarboxylic acid 528-44-9D, 1,2,4-Benzenetricarboxylic acid, enantiomers 554-95-0, 1,3,5-Benzenetricarboxylic acid 554-95-0D, 1,3,5-Benzenetricarboxylic

acid, enantiomers 586-35-6 586-35-6D, enantiomers 610-29-7
610-29-7D, enantiomers 618-83-7 618-83-7D, enantiomers 618-88-2
618-88-2D, enantiomers 636-46-4 636-46-4D, enantiomers 4315-09-7
4315-09-7D, enantiomers 6344-50-9 6344-50-9D, enantiomers 10312-55-7
10312-55-7D, enantiomers 19089-60-2 19089-60-2D, enantiomers
21615-52-1 21615-52-1D, enantiomers 22326-31-4 22326-31-4D,
enantiomers 25062-54-8 25062-54-8D, enantiomers 52137-56-1
52137-56-1D, enantiomers 76784-92-4 76784-92-4D, enantiomers
143193-46-8 143193-46-8D, enantiomers 173039-10-6 173039-10-6D,
enantiomers 173039-11-7 173039-11-7D, enantiomers 197630-75-4
197630-75-4D, enantiomers 197630-78-7 197630-78-7D, enantiomers
197630-80-1 197630-80-1D, enantiomers 197630-81-2 197630-81-2D,
enantiomers 200123-75-7 200123-75-7D, enantiomers 200698-17-5
200698-17-5D, enantiomers 200698-19-7 200698-19-7D, enantiomers
200698-20-0 200698-20-0D, enantiomers 200698-21-1 200698-21-1D,
enantiomers 200698-22-2 200698-22-2D, enantiomers 200698-23-3
200698-23-3D, enantiomers 200698-24-4 200698-24-4D, enantiomers
200698-25-5 200698-25-5D, enantiomers 200698-26-6 200698-26-6D,
enantiomers 200717-37-9 200717-37-9D, enantiomers 201041-22-7
201041-22-7D, enantiomers 209470-89-3 209470-89-3D, enantiomers
254737-18-3 254737-18-3D, enantiomers 254737-19-4 254737-19-4D,
enantiomers 254737-20-7 254737-20-7D, enantiomers 254737-21-8
254737-21-8D, enantiomers 254737-22-9 254737-22-9D, enantiomers
254737-23-0 254737-23-0D, enantiomers 254737-24-1 254737-24-1D,
enantiomers 254737-25-2 254737-25-2D, enantiomers 254737-28-5
254737-28-5D, enantiomers 254737-29-6 254737-29-6D, enantiomers
254737-30-9 254737-30-9D, enantiomers 254737-31-0 254737-31-0D,
enantiomers 254737-32-1 254737-32-1D, enantiomers 254737-33-2
254737-33-2D, enantiomers 254737-34-3 254737-34-3D, enantiomers
254737-35-4 254737-35-4D, enantiomers 254737-36-5 254737-36-5D,
enantiomers 267410-70-8 267410-70-8D, enantiomers 272128-61-7
272128-61-7D, enantiomers 272128-62-8 272128-62-8D, enantiomers
293761-62-3 293761-62-3D, enantiomers 318480-81-8 318480-81-8D,
enantiomers 377081-80-6 377081-80-6D, enantiomers 377081-81-7
377081-81-7D, enantiomers 377081-82-8 377081-82-8D, enantiomers
377081-83-9 377081-83-9D, enantiomers 377081-84-0
377081-84-0D, enantiomers 377081-85-1 377081-85-1D, enantiomers
377081-86-2 377081-86-2D, enantiomers 377081-87-3 377081-87-3D,
enantiomers 377081-88-4 377081-88-4D, enantiomers 377081-89-5
377081-89-5D, enantiomers **377081-90-8 377081-90-8D**,
enantiomers **377081-91-9 377081-91-9D**, enantiomers
377081-92-0 377081-92-0D, enantiomers **377081-93-1**
377081-93-1D, enantiomers 377081-94-2 377081-94-2D,
enantiomers 377081-95-3 377081-95-3D, enantiomers 377081-96-4
377081-96-4D, enantiomers **377081-97-5 377081-97-5D**,
enantiomers 377081-98-6 377081-98-6D, enantiomers 377081-99-7
377081-99-7D, enantiomers 377082-00-3 377082-00-3D, enantiomers
377082-01-4 377082-01-4D, enantiomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(**NAALADase** inhibitors for treating amyotrophic lateral
sclerosis)

IT 185051-07-4P 220464-68-6P 377082-02-5P 377082-03-6P 377082-04-7P
377082-05-8P 377082-06-9P 377731-27-6P 377731-29-8P 377731-30-1P
377731-31-2P 377731-32-3P 377731-33-4P 377731-34-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction; **NAALADase** inhibitors for treating
amyotrophic lateral sclerosis)

IT 122-52-1, Triethyl phosphite 358-23-6, Triflic anhydride 507-09-5,
Thioacetic acid, reactions 1003-42-5 2687-43-6, O-Benzylhydroxylamine
hydrochloride 4105-93-5 5985-24-0 7486-35-3, Tributyl(vinyl)tin
16308-65-9 91367-05-4 156750-11-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; **NAALADase** inhibitors for treating amyotrophic lateral sclerosis)

IT **9074-87-7, Naaladase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)

RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **377731-26-5P 377731-28-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)

RN 377731-26-5 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-2-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 377731-28-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



IT **377081-83-9 377081-83-9D**, enantiomers
377081-90-8 377081-90-8D, enantiomers
377081-91-9 377081-91-9D, enantiomers
377081-93-1 377081-93-1D, enantiomers
377081-97-5 377081-97-5D, enantiomers
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**NAALADase** inhibitors for treating amyotrophic lateral sclerosis)

RN 377081-83-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-83-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 4-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-90-8 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 377081-90-8 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(3-mercaptopropoxy)- (9CI) (CA INDEX NAME)



RN 377081-91-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethoxy)- (9CI) (CA INDEX NAME)



RN 377081-91-9 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethoxy)- (9CI) (CA INDEX NAME)



RN 377081-93-1 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-93-1 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 377081-97-5 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 377081-97-5 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



L102 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN **2000:661726** HCAPLUS
DN **134:25288**
TI **N-acetylated-.alpha.-linked-acidic dipeptidase** inhibitor has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced

ischemia
AU Harada, C.; Harada, T.; **Slusher, B. S.**; Yoshida, K.; Matsuda, H.; Wada, K.
CS Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502, Japan
SO Neuroscience Letters (**2000**), 292(2), 134-136
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
CC 1-11 (Pharmacology)
Section cross-reference(s): 14
AB Excessive glutamate receptor activation is thought to be involved in the **retinal** ganglion cell (RGC) death after ischemic injury. In this study, we examd. the effect of 2-PMPA (2-(phosphonomethyl)pentanedioic acid) on RGC survival in an ischemia-reperfusion model using C57BL/6 mouse eyes. 2-PMPA is a **NAALADase** (**N-acetylated-.alpha.-linked-acidic dipeptidase**) inhibitor, an enzyme responsible for the hydrolysis of the neuropeptide NAAG (N-acetyl-aspartyl-glutamate) to N-acetyl-aspartate and glutamate. 100 mg/kg 2-PMPA were given with i.p. injections 30 min before ischemia followed per h injection for 3 h. 2-PMPA increased surviving RGCs as well as **retinal** thickness after pressure-induced **retinal** ischemia. In addn., neuroprotection afforded by 2-PMPA was greater than that of N-methyl-d-aspartate receptor blocker. These data indicate that **NAALADase** inhibition may be useful in **retinal** disorders in which excessive amino acid transmission is pathogenic.
ST dipeptidase inhibitor PMPA **retinal** ischemia
IT Glutamate receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(2-PMPA has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced ischemia)
IT **Eye**
(**ganglion cell**; 2-PMPA has a neuroprotective effect on mouse **retinal ganglion cells** after pressure-induced ischemia)
IT Cytoprotective agents
(neuroprotectants; 2-PMPA has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced ischemia)
IT **Eye, disease**
(**retina, ischemia**; 2-PMPA has a neuroprotective effect on mouse **retinal ganglion cells** after pressure-induced ischemia)
IT 173039-10-6, Pentanedioic acid, 2-(phosphonomethyl)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2-PMPA has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced ischemia)
IT **9074-87-7, N-Acetylated-.alpha.-linked acidic dipeptidase**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor; 2-PMPA has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced ischemia)
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Harada, T; Neuron 2000, V26, P533 HCAPLUS
(2) Harada, T; Proc Natl Acad Sci USA 1998, V95, P4663 HCAPLUS
(3) Kashii, S; J Jpn Ophthalmol Soc 1995, V99, P1361 HCAPLUS
(4) Kristian, T; Stroke 1998, V29, P705 MEDLINE

(5) Lagreze, W; Invest Ophthalmol Vis Sci 1998, V39, P1063 MEDLINE
(6) Lipton, S; N Engl J Med 1994, V330, P613 HCAPLUS
(7) Perry, V; Neuroscience 1981, V6, P931 MEDLINE
(8) Puttfarcken, P; J Pharmacol Exp Ther 1993, V266, P796 HCAPLUS
(9) Slusher, B; Nat Med 1999, V5, P1396 HCAPLUS
(10) Stauch, B; Neurosci Lett 1989, V100, P295 HCAPLUS
(11) Sugawara, T; J Jpn Ophthalmol Soc 1992, V96, P90 HCAPLUS
(12) Tsai, G; Brain Res 1991, V518, P313
(13) Weinreb, R; Arch Ophthalmol 1999, V117, P1540 MEDLINE

IT **9074-87-7, N-Acetylated-.alpha.-linked acidic dipeptidase**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitor; 2-PMPA has a neuroprotective effect on mouse **retinal** ganglion cells after pressure-induced ischemia)
RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L102 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN **1999:750684** HCAPLUS
DN **132:149416**
TI **Glutamate carboxypeptidase** II is expressed by astrocytes in the adult rat nervous system
AU Berger, Urs V.; Luthi-Carter, Ruth; Passani, Lucius A.; Elkabes, Stella; Black, Ira; Konradi, Christine; Coyle, Joseph T.
CS Department of Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA
SO Journal of Comparative Neurology (**1999**), 415(1), 52-64
CODEN: JCNEAM; ISSN: 0021-9967
PB Wiley-Liss, Inc.
DT Journal
LA English
CC 13-1 (Mammalian Biochemistry)
Section cross-reference(s): 14
AB The enzyme **glutamate carboxypeptidase** II (GCP II) has been cloned from rat brain and human prostate. This enzyme, which catabolizes the neuropeptide N-acetylaspartylglutamate, has also been known as **N-acetylated .alpha.-linked acidic dipeptidase** (**NAALADase**), and is identical to the **prostate-specific membrane antigen** and to the jejunal **folylpoly-.gamma.-glutamate carboxypeptidase**. The goals of the present study were to elucidate the cell specificity and regional pattern of GCP II expression in the rat nervous system by using Northern blots and enzymic assays of brain and subfractionated primary neuronal and glial cultures together with in situ hybridization histochem. (ISHH) in sections of adult rat tissue. GCP II activity was assayed in astrocyte cultures (4.4 pmol/mg protein per min), neuronal-glial cocultures (2.5 pmol/mg protein per min) and neuron-enriched cultures (0.38 pmol/mg protein per min), with the activity in each prepn. correlating to its astrocytic content (r = 0.99). No activity was detected in cultured oligodendrocytes or microglia. Northern blots probed with a GCP II cDNA detected mRNAs exclusively in activity-pos. cell prepns. ISHH results show that GCP II is expressed by virtually all astrocytes, by Bergmann glial cells in cerebellum, by Muller cells in **retina** and by the satellite cells in dorsal root ganglia. Astrocytes in select groups of nuclei (e.g., habenula, supraoptic nucleus, pontine nucleus) contained pronounced levels of GCP II message. The data of the present study suggest that GCP II is expressed in the adult rat nervous system exclusively in astrocytic glial cells.

ST **glutamate carboxypeptidase** II gene expression
astrocyte glia neuron injury

IT Neuroglia
(Bergmann's cell, cerebellum, GCPII in; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT **Eye**
(Muller's cell, GCPII in; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal **injury**)

IT Brain
(cerebellum, Bergmann glial cells, GCPII in; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Brain
(corpus striatum; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Astrocyte
(**glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT mRNA
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**glutamate carboxypeptidase** II; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(**glutamate carboxypeptidase** II; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Nerve, disease
(injury; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Nerve
(neuron; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Ganglion
(satellite cell, dorsal root ganglia, GCPII in; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT Ganglion
(spinal, satellite cell, GCPII in; **glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

IT **9074-87-7, Glutamate carboxypeptidase** II
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Adams, J; J Histochem Cytochem 1992, V40, P1457 HCAPLUS
(2) Berger, U; Anat Embryol 1998, V198, P13 MEDLINE
(3) Berger, U; Anat Embryol 1998, V197, P405 MEDLINE
(4) Berger, U; Anat Embryol 1999, V199, P439 MEDLINE
(5) Berger, U; J Neurocytol 1995, V24, P99 HCAPLUS
(6) Berger, U; J Neurocytol 1996, V25, P429
(7) Blakely, R; J Neurochem 1988, V50, P1200 HCAPLUS
(8) Bzdega, T; J Neurochem 1997, V69, P2270 HCAPLUS
(9) Carter, R; Proc Natl Acad Sci USA 1996, V93, P749 HCAPLUS
(10) Cassidy, M; Neuropeptides 1993, V24, P271 HCAPLUS
(11) Chirgwin, J; Biochemistry 1979, V16, P5294
(12) Cole, R; Neuron 1995, V14, P813 HCAPLUS
(13) Coyle, J; Neurobiol Dis 1997, V4, P231 HCAPLUS
(14) Danbolt, N; Neuroscience 1992, V51, P295 HCAPLUS
(15) Dieck, S; Glia 1999, V25, P10 MEDLINE
(16) Elkabes, S; J Neurosci Res 1998, V54, P117 HCAPLUS
(17) Fuhrman, S; J Neurochem 1994, V62, P27
(18) Guarda, A; Mol Brain Res 1988, V3, P223 HCAPLUS
(19) Halsted, C; J Biol Chem 1998, V273, P20417 HCAPLUS
(20) Israeli, R; Cancer Res 1993, V53, P227 HCAPLUS
(21) Luthi-Carter, R; Brain Res 1998, V795, P341 HCAPLUS
(22) Luthi-Carter, R; J Pharmacol Exp Ther 1998, V286, P1020 HCAPLUS
(23) Luthi-Carter, R; Proc Natl Acad Sci USA 1998, V95, P3215 HCAPLUS
(24) McCarthy, K; J Cell Biol 1980, V85, P890 HCAPLUS
(25) McKinnon, R; J Cell Biol 1993, V121, P1397 HCAPLUS
(26) Meyerhoff, J; Brain Res 1992, V593, P140 HCAPLUS
(27) O'Malley, E; Brain Res 1994, V647, P83 HCAPLUS
(28) Pangalos, M; J Biol Chem 1999, V274, P8470 HCAPLUS
(29) Passani, L; Brain Res 1998, V794, P143 HCAPLUS
(30) Puttfarcken, P; J Pharmacol Exp Ther 1993, V266, P796 HCAPLUS
(31) Rawlings, N; Biochim Biophys Acta 1997, V1339, P247 HCAPLUS
(32) Robinson, M; J Biol Chem 1987, V262, P14498 HCAPLUS
(33) Rothstein, J; Ann Neurol 1990, V28, P18 HCAPLUS
(34) Schaeren-Wiemers, N; Histochemistry 1993, V100, P431 HCAPLUS
(35) Shneider, B; J Biol Chem 1997, V272, P31006 HCAPLUS
(36) Slusher, B; J Biol Chem 1990, V265, P21297 HCAPLUS
(37) Slusher, B; J Comp Neurol 1992, V315, P217 HCAPLUS
(38) Speno, H; Mol Pharmacol 1999, V55, P179 HCAPLUS
(39) Tsai, G; Arch Gen Psychiatry 1995, V52, P829 HCAPLUS
(40) Tsai, G; Brain Res 1991, V556, P151 HCAPLUS
(41) Wang, H; Am J Physiol 1998, V275, PC967 HCAPLUS
(42) Wroblewska, B; Glia 1998, V24, P172 MEDLINE
(43) Wroblewska, B; J Neurochem 1993, V61, P943 HCAPLUS
IT **9074-87-7, Glutamate carboxypeptidase II**
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(**glutamate carboxypeptidase** II (GCPII) is expressed by astrocytes in adult rat nervous system and its expression is stimulated in striatal astrocytes after neuronal injury)
RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L102 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1992:511282 HCAPLUS
DN 117:111282
TI Preparation and formulation of (5,6,7,8-tetrahydronaphthylacetamido)benzoates and analogs as drugs
IN Bernardon, Jean Michel; Pilgrim, William Robert
PA Centre International de Recherches Dermatologiques Galderma, Fr.

SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA French
IC ICM C07C069-86
ICS C07C069-76; C07C233-76; A61K031-215; A61K031-19; A61K007-00; C07C327-20; C07C069-96
CC 25-24 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9206948	A1	19920430	WO 1991-FR793	19911011 <--
	W: AU, CA, FI, HU, JP, KP, KR, NO, PL, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9188720	A1	19920520	AU 1991-88720	19911011 <--
	AU 646314	B2	19940217		
	ZA 9108126	A	19920624	ZA 1991-8126	19911011 <--
	EP 552282	A1	19930728	EP 1991-919625	19911011 <--
	EP 552282	B1	19940824		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
	JP 06502408	T2	19940317	JP 1991-518163	19911011 <--
	JP 3197011	B2	20010813		
	ES 2060413	T3	19941116	ES 1991-919625	19911011 <--
	US 5387594	A	19950207	US 1992-859522	19920804 <--
	US 5439925	A	19950808	US 1993-167145	19931216 <--
	US 5567721	A	19961022	US 1995-430622	19950428 <--
	US 5597839	A	19970128	US 1995-430615	19950428 <--
	US 5668156	A	19970916	US 1995-430613	19950428 <--
	US 5688817	A	19971118	US 1995-430612	19950428 <--
PRAI	LU 1990-87821	A	19901012 <--		
	WO 1991-FR793	A	19911011 <--		
	US 1992-859522	A3	19920804 <--		
	US 1993-167145	A3	19931216 <--		

OS MARPAT 117:111282
GI



I



II

AB Title compds. [I; R = aryl group Q; R1 = H, OH, Me, CH2OH, CO2H, alkanoyl, etc.; R2 = H, OH, alkyl, alkoxy, F, Cl, CF3, CH2OH, etc.; R3, R5 = H, OH, (cyclo) alkyl, alkoxy, etc.; R4 = groups cited for R3, F, Cl, alkylthio, etc.; R3R4 = CMe2(CH2)nCMe2; X = CH2CONH, CO2CH2, O2CO, O2CNH, COCH2O, etc.; Z = O, S, CH:CH, N:CH, etc.; n = 1, 2] were prepd. as ophthalmic, dermatol., and respiratory agents, etc. (no data). Thus,

5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene was acylated by ClCOCO2Et and the sapond. product subjected to Wolff-Kishner redn. to give, after SOCl2 treatment, the naphthylacetyl chloride which was condensed with 4-H2NC6H4CO2CH2CH:CH2 (prepn. given) to give, after (Ph3P)4Pd/morpholine treatment, title compd. II.

ST naphthylacetamidobenzoate prepn drug; dermatol naphthylacetamidobenzoate prepn; antirheumatic naphthylacetamidobenzoate prepn; ophthalmic naphthylacetamidobenzoate prepn; respiratory naphthylacetamidobenzoate prepn

IT **Eye, disease**
Lung, disease
Skin, disease
(treatment of, (tetrahydronaphthylacetamido)benzoates and analogs for)

IT Inflammation inhibitors
(antirheumatics, (tetrahydronaphthylacetamido)benzoates and analogs)

IT 1026-92-2P, Diallylterephthalate 14386-64-2P 30095-49-9P
39088-65-8P 52010-97-6P, 4-Hydroxymethylbenzaldehyde
62507-78-2P 67853-01-4P 74044-40-9P 78767-55-2P 80235-10-5P
106420-93-3P 116233-28-4P 142650-43-9P 142650-44-0P 142650-45-1P
142650-46-2P 142650-47-3P 142650-48-4P 142650-49-5P 142650-50-8P
142650-51-9P 142650-53-1P 142650-54-2P 142650-55-3P 142650-56-4P
142650-57-5P 142650-58-6P 142650-59-7P 142650-60-0P 142650-61-1P
142650-62-2P 142650-63-3P 142650-64-4P 142650-65-5P 142650-66-6P
142650-67-7P 142650-68-8P 142650-69-9P 142650-70-2P 142650-71-3P
142650-72-4P 142650-73-5P 142650-74-6P 142650-75-7P 142650-76-8P
142650-77-9P 142650-78-0P 142650-79-1P 142650-80-4P 142650-81-5P
142650-82-6P 142650-83-7P 142650-84-8P 142650-85-9P 142650-86-0P
142650-87-1P 142650-88-2P 142650-89-3P 142650-90-6P 142650-91-7P
142650-92-8P 142650-93-9P 142650-94-0P 142650-95-1P 142650-96-2P
142650-97-3P 142650-98-4P 142650-99-5P 142651-00-1P 142651-01-2P
142651-02-3P 142651-03-4P 142651-04-5P 142651-05-6P 142651-06-7P
142651-07-8P 142651-09-0P 142651-10-3P 142651-12-5P 142651-14-7P
142651-17-0P 142651-19-2P 142651-20-5P 142651-24-9P 142651-25-0P
142651-32-9P 142651-33-0P 142651-35-2P 142651-36-3P 142651-37-4P
142651-38-5P 142651-41-0P 142651-42-1P 142651-44-3P 142651-49-8P
142651-50-1P 142651-51-2P 142651-53-4P 142651-55-6P 142651-57-8P
142651-58-9P 142675-64-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of drugs)

IT 139611-74-8P 139611-75-9P 139611-76-0P 139611-77-1P 139611-78-2P
139611-80-6P 139611-81-7P 139642-37-8P 142414-06-0P 142650-22-4P
142650-23-5P 142650-24-6P 142650-25-7P 142650-26-8P 142650-27-9P
142650-28-0P 142650-29-1P 142650-30-4P 142650-31-5P 142650-32-6P
142650-33-7P 142650-34-8P 142650-35-9P 142650-36-0P 142650-37-1P
142650-38-2P 142650-39-3P 142650-40-6P 142650-41-7P 142650-42-8P
142651-08-9P 142651-11-4P 142651-13-6P 142651-15-8P 142651-16-9P
142651-18-1P 142651-21-6P 142651-22-7P 142651-23-8P 142651-26-1P
142651-27-2P 142651-28-3P 142651-29-4P 142651-30-7P 142651-34-1P
142651-39-6P 142651-40-9P 142651-43-2P 142651-45-4P 142651-46-5P
142651-47-6P 142651-48-7P 142651-52-3P 142651-56-7P 142651-59-0P
142706-02-3P 142881-23-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as drug)

IT 94-09-7, Ethyl-4-aminobenzoate 94-18-8, Benzyl-4-hydroxybenzoate
95-01-2, 2,4-Dihydroxybenzaldehyde 100-39-0, Benzyl bromide 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-61-6, Dimethyl-p-phthalate 366-84-7, Ethyl-4-aminomethylbenzoate 503-38-8 586-89-0, 4-Acetylbenzoic acid 591-20-8, 3-Bromophenol 619-58-9, 4-Iodobenzoic acid 619-66-9, 4-Formylbenzoic acid 623-05-2 768-95-6, 1-Adamantanol 1679-64-7, 4-(Methoxycarbonyl)benzoic acid 1710-98-1,

4-tert-Butylbenzoyl chloride 3147-39-5, Methyl-2,4,6-trihydroxybenzoate 4565-31-5 4755-77-5 5292-43-3, tert-Butyl-2-bromoacetate 6683-46-1 14199-15-6, Methyl-4-hydroxyphenylacetate 18469-52-8, Methyl-4-aminomethylbenzoate 22824-31-3 25804-49-3, tert-Butyl-4-hydroxybenzoate 40056-43-7 54685-31-3 69251-25-8 79557-90-7, Benzyl-2,4-dihydroxybenzoate 92050-16-3 103031-30-7 104224-50-2 104224-62-6 104224-63-7 104224-64-8 104224-76-2 132392-28-0 142651-31-8 142651-54-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of drugs)

IT **39088-65-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of drugs)

RN 39088-65-8 HCAPLUS
CN Benzoic acid, 4-(mercaptomethyl)- (9CI) (CA INDEX NAME)



L102 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 1991:656016 HCAPLUS
DN 115:256016
TI Preparation of diarylstyrylquinoline diacids as leukotriene antagonists
IN Young, Robert N.; Gauthier, Jacques Yves; Zamboni, Robert; Belley, Michel L.
PA Merck Frosst Canada, Inc., Cote d'Ivoire
SO Eur. Pat. Appl., 144 pp.
CODEN: EPXXDW
DT Patent
LA English
IC ICM C07D215-18
ICS C07D215-14; C07D215-20; C07D215-36; C07D401-12; C07D405-12; C07D409-10; A61K031-47
CC 27-17 (Heterocyclic Compounds (One Hetero Atom))
Section cross-reference(s): 1, 63
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	EP 399818	A1	19901128		EP 1990-305640	19900523	<--
	EP 399818	B1	19950816				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE						
	US 5104882	A	19920414		US 1990-527236	19900522	<--
	CA 2017376	AA	19901124		CA 1990-2017376	19900523	<--
	NO 9002301	A	19901126		NO 1990-2301	19900523	<--
	AU 9055811	A1	19901213		AU 1990-55811	19900523	<--
	ZA 9003983	A	19910327		ZA 1990-3983	19900523	<--
	JP 03072459	A2	19910327		JP 1990-132754	19900524	<--
	JP 07103107	B4	19951108				
	US 5204358	A	19930420		US 1992-818598	19920109	<--
PRAI	US 1989-356478		19890524	<--			
	US 1987-125050		19871125	<--			
	US 1988-275160		19881122	<--			
	US 1990-527236		19900522	<--			

OS MARPAT 115:256016
GI



I

AB Title compds. I [R1 = 7-Cl, 7-MeO, 6-F3C, 7-F3C, 6-MeSO2, H, 6,7-Cl2; Y = CH:CH, CH2CH2, CH2O, CHMeCH2; A = HO2C(CH2)2S, Me2NCO(CH2)2S, 3-(HO2C)C6H4S, Me3CNHCO(CH2)2S, 4-carboxy-2-pyridyl, [(1-adamantylamino)carbonylethyl]thio, 1-tetrazol-5-ylmethylthio, etc.; B = 2-(HO2C)C6H4CH2CH2, 3-(HO2C)C6H4, 5-carboxy-2-thiophenyl, HO2CCH2CHMe(CH2)2, 6-carboxy-2-pyridyl, 2-(Me3CNHCO)C6H4S, 3-[(1-tetrazol-5-yl)methyl]phenyl, etc.] and their salts, useful as inhibitors of leukotriene biosynthesis, antiasthmatic, antiallergic, antiinflammatory, and cytoprotective agents (no data, assays described), are prepd. I may also be used to treat erosive gastritis, inflammatory bowel disease, prevention of SRA-release (no data). To a suspension of [(7-chloroquinolin-2-yl)methyl]triphenylphosphonium bromide in THF was added BuLi, the reaction mixt. was stirred at -78.degree. and Me 2-[3-[2-(methoxycarbonyl)ethylthio]-3-(3-formylphenyl)propyl]benzoate [prepn. from 3-(BrCH2)C6H4CN given] added, the mixt. warmed to room temp. to give I [R1 = 7-Cl; Y = CH:CH; A = HO2C(CH2)2S; B = 2-(HO2C)C6H4CH2CH2] (II) as the di-Me ester, which in THF and MeOH was sapond. to give II.2Na salt. A capsule, injectable suspension and tablet formulations comprising I are given. Pharmaceutical compn. of I may comprise an addnl. active ingredient such as nonsteroidal antiinflammatory drug, peripheral analgesic, cyclooxygenase inhibitor, etc.

ST arylstyrylquinoline diacid prepn leukotriene antagonist; cytoprotection arylstyrylquinoline diacid; eye antiinflammatory arylstyrylquinoline diacid; antiasthmatic arylstyrylquinoline diacid; SRSA inhibitor arylstyrylquinoline diacid prepn

IT Leukotrienes
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, diarylstyrylaniline diacids)

IT Prostaglandins
Thromboxanes
RL: RCT (Reactant); RACT (Reactant or reagent)
(antagonists, leukotriene antagonists contg.)

IT Antihistaminics
(leukotriene antagonists contg.)

IT Inflammation inhibitors
(nonsteroidal, leukotriene antagonists contg.)

IT Slow-reacting substances, anaphylactic
RL: RCT (Reactant); RACT (Reactant or reagent)
(release of, inhibition of, diarylstyrylquinoline diacids for)

IT Antihistaminics
(H2, leukotriene antagonists contg.)

IT Bronchodilators
(antiasthmatics, diarylstyrylquinoline diacids)

IT **Eye, disease or disorder**
(**inflammation**, treatment of, diarylstyrylquinoline diacids for)

IT Stomach
(mucosa, protection of, diarylstyrylquinoline diacids for)

IT Analgesics
(peripheral, leukotriene antagonists contg.)

IT 1779-49-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(Wittig reaction of, with methoxybenzaldehyde)

IT 7398-63-2, Dimethylaluminum dimethylamide
RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation by, of benzoate ester)
IT 14694-95-2
RL: CAT (Catalyst use); USES (Uses)
(catalyst, for redn. of propanylbenzamide deriv.)
IT 100-42-5, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydrolysis and conversion to propanylaniline)
IT 9015-82-1, Angiotensin-converting enzyme 39391-18-9, Cyclooxygenase
61276-89-9, Thromboxane synthetase
RL: USES (Uses)
(inhibitors, leukotriene antagonists contg.)
IT 80-62-6P 91-63-4P 100-80-1P 1783-81-9P 4892-02-8P 6165-54-4P
6302-65-4P 6542-60-5P, Cyclopropaneacetonitrile 19641-29-3P
24722-19-8P 26473-47-2P 32017-77-9P 39590-81-3P,
1,1-Cyclopropanedimethanol 42392-67-6P 42392-68-7P 51130-00-8P
52178-50-4P 54051-19-3P 62778-80-7P 68348-23-2P 70097-48-2P
71063-12-2P 72886-42-1P 79473-56-6P 96685-20-0P 115104-44-4P
115104-45-5P 117843-17-1P 117843-18-2P 117843-19-3P 119327-59-2P
119327-67-2P 119327-69-4P 119327-76-3P 124037-86-1P 124037-87-2P
124037-90-7P 124037-91-8P 124037-93-0P 124037-95-2P 124037-96-3P
124037-97-4P 124037-98-5P 124037-99-6P 124038-00-2P 124038-01-3P
124038-02-4P 124038-03-5P 124038-04-6P 124038-06-8P 124038-07-9P
124038-08-0P 124038-09-1P 124038-10-4P 124038-11-5P 124038-12-6P
124038-13-7P 124038-14-8P 124038-15-9P 124038-16-0P 124038-19-3P
124038-20-6P 124038-21-7P 124038-22-8P 124038-23-9P 124038-24-0P
124038-25-1P 124038-27-3P 124038-29-5P 124038-30-8P 124038-31-9P
124038-32-0P 124038-33-1P 124038-34-2P 124038-37-5P 124038-39-7P
124038-40-0P 124038-41-1P 124038-43-3P 124038-49-9P 124038-50-2P
124038-52-4P 124038-54-6P 124038-55-7P 124038-58-0P 124061-80-9P
124061-81-0P 124061-83-2P 124679-02-3P 133768-71-5P 133772-18-6P
133772-19-7P 133772-20-0P 133772-21-1P 133772-22-2P 133772-23-3P
133772-24-4P 133772-25-5P 133772-26-6P 133772-27-7P 133772-28-8P
133772-29-9P 133772-30-2P 133772-31-3P 133772-32-4P 133772-33-5P
133772-35-7P 133772-36-8P 133772-37-9P 133772-38-0P 133772-39-1P
133772-40-4P 133772-42-6P 133772-43-7P 133772-44-8P 133772-45-9P
133772-46-0P 133772-47-1P 133772-48-2P 133772-49-3P 133772-50-6P
133772-51-7P 133772-52-8P 133772-53-9P 133772-54-0P 133772-55-1P
133772-56-2P 133772-57-3P 133772-58-4P 133772-59-5P 133772-60-8P
133772-61-9P 133772-62-0P 133772-63-1P 133772-64-2P 133772-65-3P
133772-66-4P 133772-67-5P 133772-68-6P 133772-69-7P 133772-70-0P
133772-71-1P 133772-72-2P 133772-73-3P 133772-74-4P 133772-75-5P
133772-76-6P 133772-77-7P 133772-78-8P 133772-79-9P 133772-80-2P
133772-81-3P 133772-82-4P 133772-87-9P 133791-14-7P 133791-15-8P
133791-16-9P 133791-17-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. and reaction of, on prepn. of leukotriene antagonists)
IT 124036-75-5P 124036-76-6P 124036-77-7P 124036-78-8P 124036-79-9P
124036-80-2P 124036-81-3P 124036-82-4P 124036-83-5P 124036-84-6P
124036-85-7P 124036-86-8P 124036-87-9P 124036-88-0P 124036-89-1P
124036-90-4P 124036-91-5P 124036-92-6P 124036-93-7P 124036-94-8P
124036-95-9P 124036-96-0P 124036-97-1P 124036-98-2P 124036-99-3P
124037-00-9P 124037-02-1P 124037-03-2P 124037-04-3P 124037-05-4P
124037-06-5P 124037-07-6P 124037-08-7P 124037-09-8P 124037-10-1P
124037-11-2P 124037-12-3P 124037-13-4P 124037-14-5P 124037-15-6P
124037-16-7P 124037-17-8P 124037-18-9P 124037-19-0P 124037-20-3P
124037-21-4P 124037-22-5P 124037-23-6P 124037-24-7P 124037-25-8P
124037-26-9P 124037-27-0P 124037-28-1P 124037-29-2P 124037-30-5P
124037-31-6P 124037-32-7P 124037-33-8P 124037-34-9P 124037-35-0P
124037-36-1P 124037-37-2P 124037-38-3P 124037-39-4P 124037-40-7P
124037-41-8P 124037-42-9P 124037-43-0P 124037-44-1P 124037-45-2P

124037-46-3P 124037-47-4P 124037-48-5P 124037-49-6P 124037-50-9P
124037-51-0P 124037-52-1P 124037-53-2P 124037-54-3P 124037-55-4P
124037-56-5P 124037-57-6P 124037-58-7P 124037-59-8P 124037-60-1P
124037-61-2P 124037-62-3P 124037-63-4P 124061-73-0P 124061-74-1P
124061-75-2P 124061-76-3P 124061-77-4P 124061-78-5P 124061-79-6P
133768-61-3P 133768-62-4P 133768-63-5P 133768-64-6P 133768-65-7P
133768-66-8P 133768-67-9P 133768-68-0P 133768-69-1P 133768-70-4P
133768-71-5P 133768-72-6P 133768-73-7P 133768-74-8P 133768-75-9P
133768-76-0P 133768-77-1P 133768-78-2P 133768-79-3P 133768-80-6P
133768-81-7P 133768-82-8P 133768-83-9P 133768-84-0P 133768-85-1P
133768-86-2P 133768-87-3P 133768-88-4P 133768-89-5P 133768-90-8P
133768-91-9P 133768-92-0P 133768-93-1P 133768-94-2P 133768-95-3P
133768-96-4P 133768-97-5P 133768-98-6P 133768-99-7P 133769-00-3P
133769-01-4P 133769-02-5P 133769-03-6P 133769-04-7P 133769-05-8P
133769-06-9P 133769-07-0P 133769-08-1P 133769-09-2P 133769-10-5P
133769-11-6P 133769-12-7P 133769-13-8P 133769-14-9P 133769-15-0P
133769-16-1P 133769-17-2P 133769-18-3P 133769-19-4P 133769-20-7P
133769-21-8P 133769-22-9P 133769-23-0P 133769-24-1P 133769-25-2P
133769-26-3P 133769-27-4P 133769-28-5P 133769-29-6P 133769-30-9P
133769-31-0P 133769-32-1P 133769-33-2P 133769-34-3P 133769-35-4P
133769-36-5P 133769-37-6P 133769-38-7P 133769-39-8P 133769-40-1P
133769-41-2P 133769-42-3P 133769-43-4P 133769-44-5P 133769-45-6P
133769-46-7P 133769-47-8P 133769-48-9P 133769-49-0P 133769-50-3P
133769-51-4P 133769-52-5P 133769-53-6P 133769-54-7P 133769-55-8P
133769-56-9P 133769-57-0P 133769-58-1P 133769-59-2P 133769-60-5P
133769-61-6P 133769-62-7P 133769-63-8P 133769-64-9P 133769-65-0P
133769-66-1P 133769-67-2P 133769-68-3P 133769-69-4P 133769-70-7P
133769-71-8P 133769-72-9P 133769-73-0P 133769-74-1P 133769-75-2P
133769-76-3P 133769-77-4P 133769-78-5P 133769-79-6P 133769-80-9P
133769-81-0P 133769-82-1P 133769-83-2P 133769-84-3P 133769-85-4P
133769-86-5P 133769-87-6P 133769-88-7P 133769-89-8P 133769-90-1P
133769-91-2P 133769-92-3P 133769-93-4P 133769-94-5P 133769-95-6P
133769-96-7P 133769-97-8P 133769-98-9P 133769-99-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as leukotriene antagonist)

IT 133770-00-0P 133770-01-1P 133770-02-2P 133770-03-3P 133770-04-4P
133770-05-5P 133770-06-6P 133770-07-7P 133770-08-8P 133770-09-9P
133770-10-2P 133770-11-3P 133770-12-4P 133770-13-5P 133770-14-6P
133770-15-7P 133770-16-8P 133770-17-9P 133770-18-0P 133770-19-1P
133770-20-4P 133770-21-5P 133770-22-6P 133770-23-7P 133770-24-8P
133770-25-9P 133770-26-0P 133770-27-1P 133770-28-2P 133770-29-3P
133770-30-6P 133770-31-7P 133770-32-8P 133770-33-9P 133770-34-0P
133770-35-1P 133770-36-2P 133770-37-3P 133770-38-4P 133770-39-5P
133770-40-8P 133770-41-9P 133770-42-0P 133770-43-1P 133770-44-2P
133770-45-3P 133770-46-4P 133770-47-5P 133770-48-6P 133770-49-7P
133770-50-0P 133770-51-1P 133770-52-2P 133770-53-3P 133770-54-4P
133770-55-5P 133770-56-6P 133770-57-7P 133770-58-8P 133770-59-9P
133770-60-2P 133770-61-3P 133770-62-4P 133770-63-5P 133770-64-6P
133770-65-7P 133770-66-8P 133770-67-9P 133770-68-0P 133770-69-1P
133770-70-4P 133770-71-5P 133770-72-6P 133770-73-7P 133770-74-8P
133770-75-9P 133770-76-0P 133770-77-1P 133770-78-2P 133770-79-3P
133770-80-6P 133770-81-7P 133770-82-8P 133770-83-9P 133770-84-0P
133770-85-1P 133770-86-2P 133770-87-3P 133770-88-4P 133770-89-5P
133770-90-8P 133770-91-9P 133770-92-0P 133770-93-1P 133770-94-2P
133770-95-3P 133770-96-4P 133770-97-5P 133770-98-6P 133770-99-7P
133771-00-3P 133771-01-4P 133771-02-5P 133771-03-6P 133771-04-7P
133771-05-8P 133771-06-9P 133771-07-0P 133771-08-1P 133771-09-2P
133771-10-5P 133771-11-6P 133771-12-7P 133771-13-8P 133771-14-9P
133771-15-0P 133771-16-1P 133771-17-2P 133771-18-3P 133771-19-4P
133771-20-7P 133771-21-8P 133771-22-9P 133771-23-0P 133771-24-1P
133771-25-2P 133771-26-3P 133771-27-4P 133771-28-5P 133771-29-6P

133771-30-9P 133771-31-0P 133771-32-1P 133771-33-2P 133771-34-3P
133771-35-4P 133771-36-5P 133771-37-6P 133771-38-7P 133771-39-8P
133771-40-1P 133771-41-2P 133771-42-3P 133771-43-4P 133771-44-5P
133771-45-6P 133771-46-7P 133771-47-8P 133771-48-9P 133771-49-0P
133771-50-3P 133771-51-4P 133771-52-5P 133771-53-6P 133771-54-7P
133771-55-8P 133771-56-9P 133771-57-0P 133771-58-1P 133771-59-2P
133771-60-5P 133771-61-6P 133771-62-7P 133771-63-8P 133771-64-9P
133771-65-0P 133771-66-1P 133771-67-2P 133771-68-3P 133771-69-4P
133771-70-7P 133771-71-8P 133771-72-9P 133771-73-0P 133771-74-1P
133771-75-2P 133771-76-3P 133771-77-4P 133771-78-5P 133771-79-6P
133771-80-9P 133771-81-0P 133771-82-1P 133771-83-2P 133771-84-3P
133771-85-4P 133771-86-5P 133771-87-6P 133771-88-7P 133771-89-8P
133771-90-1P 133771-91-2P 133771-92-3P 133771-93-4P 133771-94-5P
133771-95-6P 133771-96-7P 133771-97-8P 133771-98-9P 133771-99-0P
133772-00-6P 133772-01-7P 133772-02-8P 133772-03-9P 133772-04-0P
133772-05-1P 133772-06-2P 133772-07-3P 133772-08-4P 133772-09-5P
133772-10-8P 133772-11-9P 133772-12-0P 133772-13-1P 133772-14-2P
133772-15-3P 133772-16-4P 133772-17-5P 133791-04-5P 133791-05-6P
133791-06-7P 133791-07-8P 133791-08-9P 133791-09-0P 133791-10-3P
133791-11-4P 133791-12-5P 133791-13-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as leukotriene antagonist)

IT 75-64-9, reactions 79-44-7 88-65-3 95-76-1 97-63-2 100-53-8, Benzenemethanethiol 104-88-1, reactions 107-21-1, 1,2-Ethanediol, reactions 107-96-0 128-37-0, reactions 147-93-3 288-94-8, 1H-Tetrazole 507-09-5, Ethanethioic acid, reactions 527-72-0, 2-Thiophenecarboxylic acid 585-76-2 591-31-1 598-98-1 603-35-0, reactions 626-19-7, 1,3-Benzenedicarboxaldehyde 665-66-7 824-98-6 1078-28-0 2417-73-4 2935-90-2 3070-65-3 4170-30-3, 2-Butenal 4965-33-7 7051-34-5 7398-63-2 15852-73-0 16420-13-6 17846-68-3 19438-10-9 20826-04-4 21739-92-4 22813-58-7 22948-02-3 24964-64-5 25952-53-8 26473-47-2 26673-32-5 28188-41-2 32365-96-1 35040-68-7 **38335-14-7** 42900-89-0 43161-30-4 51635-55-3 58479-61-1 70124-54-8 80750-11-4 89794-72-9 92065-71-9 104208-14-2 115104-25-1 115104-30-8 115104-40-0 115125-09-2 119327-65-0 124038-26-2 124038-36-4 124038-48-8 124038-53-5 133772-53-9 133772-59-5 133772-83-5 133772-84-6 133772-85-7 **133772-86-8** 133772-88-0 133772-89-1 133772-90-4 133772-91-5 133775-83-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of leukotriene antagonists)

IT 1559-02-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(redn. of)

IT **38335-14-7 133772-86-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of leukotriene antagonists)

RN 38335-14-7 HCAPLUS
CN Benzoic acid, 2-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 133772-86-8 HCAPLUS
CN Benzoic acid, 5-chloro-2-(mercaptomethyl)- (9CI) (CA INDEX NAME)



=> d l103 all hitstr tot

L103 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:927395 HCAPLUS
DN 138:13959
TI Thiolalkyl **benzoic** acid derivatives [i.e., (mercaptoalkyl) **benzoic** acids] with **NAALADase** inhibitory activity, and their use as neuroprotectants, etc.
IN Tsukamoto, Takashi; Stoermer, Doris; Vitharana, Dilrukshi
PA **Guilford Pharmaceuticals Inc., USA**
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C323-56
ICS C07C323-58; C07C323-62; A61K031-095; A61P025-00; A61P035-00
CC 25-17 (**Benzene**, Its Derivatives, and Condensed **Benzenoid** Compounds)
Section cross-reference(s): 1, 7
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096866	A2	20021205	WO 2002-US16971	20020530

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-294036P P 20010530
US 2001-342746P P 20011228
OS MARPAT 138:13959
GI



I



II



III

AB The invention relates to new thiolalkyl **benzoic** acids, pharmaceutical compns. and diagnostic kits comprising such compds., and methods of using such compds. Uses of the compds. include: inhibiting **NAALADase** enzyme activity, detecting diseases where **NAALADase** levels are altered, effecting neuronal activity, effecting TGF-.beta. activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers, **glaucoma**, **retinal** disorders, and cancer. In particular, compds. I and II are claimed [wherein: R1, R2, R3, and R4 are independently H or C1-C3 alkyl; and A1, A2, A3, and A4 are independently H, C1-C9 alkyl, C2-C9 alkenyl, C2-C9 alkynyl, aryl, heteroaryl, carbocycle, heterocycle, halo, OH, sulfhydryl, NO2, amino, cyano, isocyano, thiocyano, isothiocyano, formamido, thioformamido, sulfo, sulfino, C1-C9 alkylsulfonyl, C1-C9 alkoxy, C2-C9 alkenoxy, phenoxy, or benzyloxy; wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, heterocycle, alkoxy, alkenoxy, phenoxy, and benzyloxy groups are independently unsubstituted or substituted with one or more substituent(s); for II, if A1 is Cl, F, amino, or thiomethyl, then all of A2, A3, and A4 may not be H; also, at least one A group is not H]. Approx. 50 example compds. were prepd., tested, and/or claimed. For instance, 2,2-dimethyl-5-[(trifluoromethanesulfonyl)oxy]-4H-1,3-**benzodioxin**-4-one was arylated with 3-(ethoxycarbonyl)phenylboronic acid, followed by alk. methanolysis to give 3-hydroxy-[1,1'-biphenyl]-2,3'-dicarboxylic acid di-Me ester. This phenol deriv. was converted to a triflate, vinylated with Bu3SnCH:CH2, acylthiolated with AcSH and AIBN, and hydrolyzed in 2 steps, to give title compd. III. This compd. inhibited **NAALADase** in vitro, and was active at 0.1 mg/kg in the CCI neuropathic pain model in rats (sciatic nerve ligation/thermal pain response).

ST thiolalkyl **benzoic** acid prepn **NAALADase** inhibitor neuroprotectant; mercaptoalkylbenzoate prepn treatment neurodegeneration cancer angiogenesis inflammation pain **glaucoma**

IT Nervous system
(Huntington's chorea, treatment of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT Nervous system
(amyotrophic lateral sclerosis, treatment of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT Nerve, disease

(degeneration, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Nerve, disease
(demyelination, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Nerve, disease
(diabetic neuropathy, treatment of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Connective tissue
Nervous system
Prostate gland
(disease, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Fertility
Immunity
Memory, biological
(disorder, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Spinal cord
(injury, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Nerve, disease
(neuropathy, treatment of pain; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Cytoprotective agents
(neuroprotectants; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Mental disorder
(obsession-compulsion, treatment of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Nerve, disease
(peripheral neuropathy, treatment of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Analgesics
Angiogenesis inhibitors
Anti-inflammatory agents
Anti-ischemic agents
Antidiabetic agents
Antiglaucoma agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Anxiolytics
Cognition enhancers
Immunomodulators
Nervous system agents
(prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Skin, disease
(scar, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Brain, disease
(stroke, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Brain, disease
(trauma, treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Extracellular matrix
(treatment of disease; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT Cell proliferation
(treatment of related diseases; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Anti-infective agents
Anxiety
Diabetes mellitus
Fibrosis
Glaucoma (disease)
Inflammation
Ischemia
Neoplasm
Pain
Parkinson's disease
Respiratory distress syndrome
Schizophrenia
(treatment of; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.-, enhancement of secretion; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT 173039-10-6, 2-(Phosphonomethyl)pentanedioic acid 200698-26-6, 2-[[(2,3,4,5,6-Pentafluorobenzyl)hydroxyphosphinyl]methyl]pentanedioic acid 254737-18-3, 2-(2-Sulfanylethyl)pentanedioic acid 254737-29-6, 2-(3-Sulfanylpropyl)pentanedioic acid **377731-28-7**, 3-Carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl) **benzenepropanoic** acid **378242-22-9**, 3-Carboxy-.alpha.-(3-mercaptopropyl)**benzenepropanoic** acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison compd.; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
IT **28162-88-1P**, 3-(Mercaptomethyl)**benzoic** acid
38335-14-7P, 2-(Mercaptomethyl)**benzoic** acid
378242-00-3P, 3-(2-Mercaptoethyl)[1,1'-biphenyl]-2,3'-dicarboxylic acid **378242-07-0P**, 2-[(4-Carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-12-7P**, 4-(Mercaptomethyl)[1,1'-biphenyl]-2,3'-dicarboxylic acid **378242-67-2P**, 3-(2-Mercaptoethyl)**benzoic** acid **378242-68-3P**, 5-Hydroxy-2-(2-mercaptoethyl)**benzoic** acid **378242-69-4P**, 2-(2-Mercaptoethyl)**benzoic** acid **378242-70-7P**, 5-[(4-Carboxyphenyl)methoxy]-2-(2-mercaptoethyl) **benzoic** acid **378242-71-8P**, 2-(2-Mercaptoethyl)-5-(phenylmethoxy)**benzoic** acid **378242-72-9P**, 2-(Carboxymethoxy)-6-(2-mercaptoethyl)**benzoic** acid **378242-74-1P**, 2-(2-Mercaptoethyl)-6-(phenylmethoxy)**benzoic** acid **378242-75-2P**, 2-[(2-Carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-76-3P**, 2-(3,3-Dimethylbutoxy)-6-(2-mercaptoethyl)**benzoic** acid **378242-77-4P**, 2-(2-Mercaptoethyl)-6-(2-phenylethoxy) **benzoic** acid **378242-78-5P**, 2-[(2-Chlorophenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-79-6P**, 2-[[3-Carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl) **benzoic** acid **378242-80-9P**, 2-(2-Mercaptoethyl)-6-phenoxybenzoic acid **378242-81-0P**, 2-(2-Mercaptoethyl)-6-(phenylamino)**benzoic** acid **378242-82-1P**, 2-(2-Mercaptoethyl)-6-(phenylthio)**benzoic** acid **378242-83-2P**, 5'-(1,1-Dimethylethyl)-3-(2-mercaptoethyl)[1,1'-biphenyl]-2,3'-dicarboxylic acid **378242-84-3P**, 3-(2-Mercaptoethyl)[1,1'-biphenyl]-2,4'-dicarboxylic acid **378242-85-4P**, 2-[(4-Carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-86-5P**,

2-[(4-Carboxy-3-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-88-7P**, 2-[(2-Bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-89-8P**, 2-[(3-Bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-90-1P**, 2-[(4-Chlorophenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-91-2P**, 2-(Biphenyl-2-ylmethoxy)-6-(2-mercaptoethyl)**benzoic** acid **378242-92-3P**, 2-[(3-Bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-93-4P**, 2-[(2-Bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-94-5P**, 2-(2-Mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]**benzoic** acid **378242-95-6P**, 2-(2-Mercaptoethyl)-6-[(4-methylphenyl)methoxy]**benzoic** acid **378242-96-7P**, 2-[(4-Bromo-3-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-97-8P**, 2-[(2-Carboxy-5-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-98-9P**, 5-(Mercaptomethyl)-2-(2-phenylethoxy)**benzoic** acid **378242-99-0P**, 2-Bromo-5-(mercaptomethyl)**benzoic** acid **378243-00-6P**, 5-(Mercaptomethyl)-2-(phenylmethoxy)**benzoic** acid **378243-01-7P**, 4-Bromo-3-(mercaptomethyl)**benzoic** acid **477351-08-9P**, 5-[(3-Carboxyphenyl)methoxy]-2-(2-mercaptoethyl)**benzoic** acid **477351-09-0P**, 2-[(3-Carboxybenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid **477351-10-3P**, 2-[(4-Bromobenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid **477351-11-4P**, 2-[(4-tert-Butylbenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid **477351-12-5P**, 2-[(3-Bromobenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid **477351-13-6P**, 2-(2-Mercaptoethyl)-6-methoxybenzoic acid **477351-14-7P**, 2-(Benzhydryloxy)-6-(2-mercaptoethyl)**benzoic** acid **477351-15-8P**, 2-[(3-Chlorobenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid **477351-16-9P**, 3-(2-Mercaptoethyl)biphenyl-2-carboxylic acid **477351-17-0P**, 2-(Carboxymethyl)-6-(2-mercaptoethyl)**benzoic** acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT 43071-26-7P, 2-Hydroxy-6-[(methoxycarbonyl)methyl]**benzoic** acid methyl ester 378242-01-4P, 3-(2,2-Dimethyl-4-oxo-4H-1,3-**benzodioxin**-5-yl)**benzoic** acid ethyl ester 378242-02-5P, 3-Hydroxy-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 378242-03-6P, 3-[(Trifluoromethanesulfonyl)oxy]-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 378242-04-7P, 3-Ethenyl-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 378242-05-8P, 3-[2-(Acetylthio)ethyl]-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester **378242-06-9P**, 3-(2-Mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid 2-methyl ester 378242-08-1P, 5-Ethenyl-2,2-dimethyl-4H-1,3-**benzodioxin**-4-one 378242-09-2P, 2-Ethenyl-6-hydroxybenzoic acid methyl ester 378242-10-5P, 2-Ethenyl-6-[[4-(methoxycarbonyl)phenyl]methoxy]**benzoic** acid methyl ester 378242-13-8P, 4-Methyl[1,1'-biphenyl]-2,3'-dicarboxylic acid 378242-15-0P, 4-Methyl[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 378242-16-1P, 4-(Bromomethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 378242-17-2P, 4-[(Acetylthio)methyl]-[1,1'-biphenyl]-2,3'-dicarboxylic acid dimethyl ester 477351-18-1P, 2-[2-(Acetylthio)ethyl]-6-[[4-(methoxycarbonyl)phenyl]methoxy]**benzoic** acid methyl ester 477351-19-2P, 2-[(Methoxycarbonyl)methyl]-6-

[(trifluoromethanesulfonyl)oxy]**benzoic** acid methyl ester 477351-20-5P, 2-[(Methoxycarbonyl)methyl]-6-vinylbenzoic acid methyl ester 477351-21-6P, 2-[2-(Acetylsulfanyl)ethyl]-6-[(methoxycarbonyl)methyl] **benzoic** acid methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT 2417-72-3, Methyl 4-(bromomethyl)**benzoate** 4334-87-6, 3-(Ethoxycarbonyl)phenylboronic acid 6967-82-4, 2-Bromo-5-methylbenzoic acid 25487-66-5, 3-Carboxyphenylboronic acid 42421-12-5, 2-(Carboxymethyl)-6-hydroxybenzoic acid 164014-40-8, 2,2-Dimethyl-5-[(trifluoromethanesulfonyl)oxy]-4H-1,3-**benzodioxin** -4-one
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT 56-86-0, L-Glutamic acid, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(treatment of abnormalities in biol. of; prepn. of (thioalkyl) **benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

IT **377731-28-7**, 3-Carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl)**benzenepropanoic** acid **378242-22-9**, 3-Carboxy-.alpha.-(3-mercaptopropyl)**benzenepropanoic** acid
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(comparison compd.; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)

RN 377731-28-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-22-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



IT **28162-88-1P**, 3-(Mercaptomethyl)**benzoic** acid **38335-14-7P**, 2-(Mercaptomethyl)**benzoic** acid **378242-00-3P**, 3-(2-Mercaptoethyl)[1,1'-biphenyl]-2,3'-dicarboxylic acid **378242-07-0P**, 2-[(4-Carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic** acid **378242-12-7P**, 4-(Mercaptomethyl)[1,1'-biphenyl]-2,3'-dicarboxylic acid

378242-67-2P, 3-(2-Mercaptoethyl)**benzoic** acid
378242-68-3P, 5-Hydroxy-2-(2-mercaptoethyl)**benzoic** acid
378242-69-4P, 2-(2-Mercaptoethyl)**benzoic** acid
378242-70-7P, 5-[(4-Carboxyphenyl)methoxy]-2-(2-mercaptoethyl)
benzoic acid **378242-71-8P**, 2-(2-Mercaptoethyl)-5-
(phenylmethoxy)**benzoic** acid **378242-72-9P**,
2-(Carboxymethoxy)-6-(2-mercaptoethyl)**benzoic** acid
378242-74-1P, 2-(2-Mercaptoethyl)-6-(phenylmethoxy)**benzoic**
acid **378242-75-2P**, 2-[(2-Carboxyphenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-76-3P**,
2-(3,3-Dimethylbutoxy)-6-(2-mercaptoethyl)**benzoic** acid
378242-77-4P, 2-(2-Mercaptoethyl)-6-(2-phenylethoxy)
benzoic acid **378242-78-5P**, 2-[(2-Chlorophenyl)methoxy]-6-
(2-mercaptoethyl)**benzoic** acid **378242-79-6P**,
2-[[3-Carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)
benzoic acid **378242-80-9P**, 2-(2-Mercaptoethyl)-6-
phenoxybenzoic acid **378242-81-0P**, 2-(2-Mercaptoethyl)-6-
(phenylamino)**benzoic** acid **378242-82-1P**,
2-(2-Mercaptoethyl)-6-(phenylthio)**benzoic** acid
378242-83-2P, 5'-(1,1-Dimethylethyl)-3-(2-mercaptoethyl)[1,1'-
biphenyl]-2,3'-dicarboxylic acid **378242-84-3P**,
3-(2-Mercaptoethyl)[1,1'-biphenyl]-2,4'-dicarboxylic acid
378242-85-4P, 2-[(4-Carboxy-2-methoxyphenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-86-5P**,
2-[(4-Carboxy-3-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic**
acid **378242-88-7P**, 2-[(2-Bromo-4-carboxyphenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-89-8P**,
2-[(3-Bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic**
acid **378242-90-1P**, 2-[(4-Chlorophenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-91-2P**,
2-(Biphenyl-2-ylmethoxy)-6-(2-mercaptoethyl)**benzoic** acid
378242-92-3P, 2-[(3-Bromo-5-carboxyphenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-93-4P**,
2-[(2-Bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic**
acid **378242-94-5P**, 2-(2-Mercaptoethyl)-6-[(4-
methoxyphenyl)methoxy]**benzoic** acid **378242-95-6P**,
2-(2-Mercaptoethyl)-6-[(4-methylphenyl)methoxy]**benzoic** acid
378242-96-7P, 2-[(4-Bromo-3-carboxyphenyl)methoxy]-6-(2-
mercaptoethyl)**benzoic** acid **378242-97-8P**,
2-[(2-Carboxy-5-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)**benzoic**
acid **378242-98-9P**, 5-(Mercaptomethyl)-2-(2-phenylethoxy)
benzoic acid **378242-99-0P**, 2-Bromo-5-(mercaptomethyl)
benzoic acid **378243-00-6P**, 5-(Mercaptomethyl)-2-
(phenylmethoxy)**benzoic** acid **378243-01-7P**,
4-Bromo-3-(mercaptomethyl)**benzoic** acid **477351-08-9P**,
5-[(3-Carboxyphenyl)methoxy]-2-(2-mercaptoethyl)**benzoic** acid
477351-09-0P, 2-[(3-Carboxybenzyl)oxy]-6-(2-mercaptoethyl)
benzoic acid **477351-10-3P**, 2-[(4-Bromobenzyl)oxy]-6-(2-
mercaptoethyl)**benzoic** acid **477351-11-4P**,
2-[(4-tert-Butylbenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid
477351-12-5P, 2-[(3-Bromobenzyl)oxy]-6-(2-mercaptoethyl)
benzoic acid **477351-13-6P**, 2-(2-Mercaptoethyl)-6-
methoxybenzoic acid **477351-14-7P**, 2-(Benzhydryloxy)-6-(2-
mercaptoethyl)**benzoic** acid **477351-15-8P**,
2-[(3-Chlorobenzyl)oxy]-6-(2-mercaptoethyl)**benzoic** acid
477351-16-9P, 3-(2-Mercaptoethyl)biphenyl-2-carboxylic acid
477351-17-0P, 2-(Carboxymethyl)-6-(2-mercaptoethyl)**benzoic**
acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; prepn. of (thioalkyl)**benzoic** acid derivs. as
NAALADase inhibitors and neuroprotectants)

RN 28162-88-1 HCAPLUS
CN Benzoic acid, 3-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 38335-14-7 HCAPLUS
CN Benzoic acid, 2-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378242-00-3 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-07-0 HCAPLUS
CN Benzoic acid, 2-[(4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-12-7 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 4-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378242-67-2 HCAPLUS
CN Benzoic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-68-3 HCAPLUS
CN Benzoic acid, 5-hydroxy-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-69-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-70-7 HCAPLUS
CN Benzoic acid, 5-[(4-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-71-8 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-72-9 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-74-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378242-75-2 HCAPLUS
CN Benzoic acid, 2-[(2-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-76-3 HCAPLUS
CN Benzoic acid, 2-(3,3-dimethylbutoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-77-4 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-78-5 HCAPLUS
CN Benzoic acid, 2-[(2-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA

INDEX NAME)



RN 378242-79-6 HCAPLUS
CN Benzoic acid, 2-[[3-carboxy-5-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-80-9 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-phenoxy- (9CI) (CA INDEX NAME)



RN 378242-81-0 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylamino)- (9CI) (CA INDEX NAME)



RN 378242-82-1 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-(phenylthio)- (9CI) (CA INDEX NAME)



RN 378242-83-2 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 5'-(1,1-dimethylethyl)-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-84-3 HCAPLUS
CN [1,1'-Biphenyl]-2,4'-dicarboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)





RN 378242-85-4 HCAPLUS
CN Benzoic acid, 2-[(4-carboxy-2-methoxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-86-5 HCAPLUS
CN Benzoic acid, 4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 378242-88-7 HCAPLUS
CN Benzoic acid, 2-[(2-bromo-4-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-89-8 HCAPLUS
CN Benzoic acid, 2-bromo-4-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-90-1 HCAPLUS
CN Benzoic acid, 2-[(4-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-91-2 HCAPLUS
CN Benzoic acid, 2-([1,1'-biphenyl]-2-ylmethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-92-3 HCAPLUS
CN Benzoic acid, 2-[(3-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-93-4 HCAPLUS

CN Benzoic acid, 2-[(2-bromo-5-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 378242-94-5 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-95-6 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-[(4-methylphenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 378242-96-7 HCAPLUS
CN Benzoic acid, 2-bromo-5-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 378242-97-8 HCAPLUS
CN Benzoic acid, 2-[[2-carboxy-3-(2-mercaptoethyl)phenoxy]methyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 378242-98-9 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(2-phenylethoxy)- (9CI) (CA INDEX NAME)



RN 378242-99-0 HCAPLUS
CN Benzoic acid, 2-bromo-5-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 378243-00-6 HCAPLUS
CN Benzoic acid, 5-(mercaptomethyl)-2-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378243-01-7 HCAPLUS
CN Benzoic acid, 4-bromo-3-(mercaptomethyl)- (9CI) (CA INDEX NAME)



RN 477351-08-9 HCAPLUS

CN Benzoic acid, 5-[(3-carboxyphenyl)methoxy]-2-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-09-0 HCAPLUS
CN Benzoic acid, 2-[(3-carboxyphenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-10-3 HCAPLUS
CN Benzoic acid, 2-[(4-bromophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-11-4 HCAPLUS
CN Benzoic acid, 2-[[4-(1,1-dimethylethyl)phenyl]methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-12-5 HCAPLUS
CN Benzoic acid, 2-[(3-bromophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-13-6 HCAPLUS
CN Benzoic acid, 2-(2-mercaptoethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 477351-14-7 HCAPLUS
CN Benzoic acid, 2-(diphenylmethoxy)-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-15-8 HCAPLUS
CN Benzoic acid, 2-[(3-chlorophenyl)methoxy]-6-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-16-9 HCAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



RN 477351-17-0 HCAPLUS
CN Benzeneacetic acid, 2-carboxy-3-(2-mercaptoethyl)- (9CI) (CA INDEX NAME)



IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **378242-06-9P**, 3-(2-Mercaptoethyl)-[1,1'-biphenyl]-2,3'-dicarboxylic acid 2-methyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of (thioalkyl)**benzoic** acid derivs. as **NAALADase** inhibitors and neuroprotectants)
RN 378242-06-9 HCAPLUS
CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 3-(2-mercaptoethyl)-, 2-methyl ester (9CI) (CA INDEX NAME)



L103 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:888696 HCAPLUS
DN 137:380049
TI Hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors,preparation, and therapeutic and diagnostic use thereof
IN Tsukamoto, Takashi; Liu, Qun; Xu, Weizheng; Majer, Pavel; Hin, Bunda; Stoermer, Doris
PA **Guilford Pharmaceuticals Inc., USA**
SO PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C259-06
ICS C07C323-60; C07C317-44; A61K031-10; A61K031-16
CC 1-12 (Pharmacology)
Section cross-reference(s): 9, **25**, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092553	A1	20021121	WO 2002-US14635	20020510

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-290015P P 20010511
US 2001-342741P P 20011228
OS MARPAT 137:380049
AB The invention provides compds., pharmaceutical compns. and diagnostic kits

comprising such compds., and methods of using such compds. for inhibiting **NAALADase** enzyme activity, detecting diseases where **NAALADase** levels are altered, effecting neuronal activity, effecting TGF-.beta. activity, inhibiting angiogenesis, and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancers and **glaucoma**.

ST hydroxamic acid hydroxylamine compd **NAALADase** inhibitor prepn therapeutic diagnostic; TGF modulation hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; nervous system agent hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; angiogenesis inhibitor hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; glutamate disease hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; neuropathy pain hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; compulsive disorder hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; prostate disease hydroxamic acid hydroxylamine compd **NAALADase** inhibitor; cancer **glaucoma** hydroxamic acid hydroxylamine compd **NAALADase** inhibitor

IT Nervous system
(Huntington's chorea; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Diagnosis
(agents; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Nervous system
(amyotrophic lateral sclerosis; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Cell proliferation
(cell growth-related disease; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Blood vessel, disease
(collagen vascular disease; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(collagen vascular disease; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Mental disorder
(compulsive; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Nerve, disease
(degeneration; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Nerve, disease
(demyelination; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Nerve, disease
(diabetic neuropathy; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Connective tissue
Nervous system
Prostate gland
(disease; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Fertility
Immunity
Memory, biological
(disorder; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Epithelium
(epithelial tissue scarring; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Disease, animal
(fibroproliferative; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Extracellular matrix
(formation disorder; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Analgesics
Angiogenesis inhibitors
Anti-infective agents
Anti-inflammatory agents
Anti-ischemic agents
Antidiabetic agents
Antiglaucoma agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Anxiety
Anxiolytics
Cardiovascular agents
Cognition enhancers
Cytotoxic agents
Diabetes mellitus
Diagnosis
Drug delivery systems
Glaucoma (disease)
Imaging agents
Infection
Inflammation
Neoplasm
Nervous system agents
Pain
Parkinson's disease
Respiratory distress syndrome
Schizophrenia
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Brain, disease
Nerve, disease
Spinal cord
(injury; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Brain, disease
(ischemia; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Regeneration, animal
(nerve; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT Pain
(neuropathic; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic

use)
IT Nerve, disease
(neuropathy, neuropathic pain; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Cytoprotective agents
(neuroprotectants; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Nerve, disease
(peripheral neuropathy, from phys. injury or disease; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Nerve
(regeneration; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Brain, disease
(stroke; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Brain, disease
(trauma; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.-, modulators; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.1-; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT Transforming growth factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.beta.2-; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT 56-86-0, L-Glutamic acid, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glutamate abnormalities; hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT 378243-50-6P 475653-67-9P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
IT 4743-99-1 173039-10-6 200698-26-6 254737-18-3 254737-29-6
378243-04-0 378243-05-1 378243-06-2 378243-07-3 378243-08-4
378243-09-5 378243-10-8 378243-11-9 378243-12-0 378243-13-1
378243-14-2 378243-15-3 378243-16-4 378243-17-5 378243-18-6
378243-19-7 378243-20-0 378243-21-1 378243-22-2 378243-23-3
378243-24-4 378243-25-5 378243-26-6 378243-27-7 378243-28-8
378243-29-9 378243-30-2 378243-31-3 378243-32-4 378243-33-5
378243-34-6 378243-35-7 378243-36-8 378243-63-1 475653-40-8
475653-41-9 475653-42-0 475653-43-1 475653-44-2 475653-45-3
475653-46-4 475653-47-5 475653-48-6 475653-49-7 475653-50-0

475653-51-1 475653-52-2 475653-53-3 475653-54-4 475653-55-5
475653-56-6 **475653-68-0 475653-69-1**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT 622-33-3, O-Benzylhydroxylamine 830-79-5, 2,4,6-Trimethoxybenzaldehyde 2417-72-3, Methyl 4-(bromomethyl)**benzoate** 2687-43-6 3196-15-4 3395-91-3 36239-09-5, Ethyl malonyl chloride 88987-42-2 378242-02-5 **378242-22-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

IT 475653-57-7P 475653-58-8P 475653-59-9P 475653-60-2P 475653-61-3P 475653-62-4P 475653-63-5P 475653-64-6P 475653-65-7P 475653-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Guilford Pharm Inc; WO 9845256 A 1998 HCAPLUS
(2) Guilford Pharm Inc; WO 0192274 A 2001 HCAPLUS
(3) Kaczka, E; US 3282986 A 1966 HCAPLUS
(4) Shell Int Research; EP 0057027 A 1982 HCAPLUS

IT **9074-87-7, NAALADase**
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

RN 9074-87-7 HCAPLUS
CN Hydrolase, .gamma.-glutamyl (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **475653-68-0 475653-69-1**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)

RN 475653-68-0 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.beta.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 475653-69-1 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.beta.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



IT **378242-22-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydroxamic acids and acyl hydroxylamines as **NAALADase** inhibitors, prepn., and therapeutic and diagnostic use)
RN 378242-22-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



L103 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:555453 HCAPLUS
DN 137:124986
TI Preparation of thiol-based **NAALADase** inhibitors and their uses thereof
IN Tsukamoto, Takashi; Majer, Pavel; Stoermer, Doris; **Slusher, Barbara S.**
PA **Guilford Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C323-56
ICS A61K031-095; A61P025-00; A61P035-00; C07C323-52; C07C323-58; C07C323-59; C07C323-60; C07C323-62; C07C323-65
CC 25-17 (**Benzene**, Its Derivatives, and Condensed **Benzenoid** Compounds)
Section cross-reference(s): 1, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002057222	A2	20020725	WO 2002-US1205	20020117
WO 2002057222	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-261754P P 20010117
US 2001-342772P P 20011228

OS MARPAT 137:124986

AB This invention relates to new compds., pharmaceutical compns. and diagnostic kits comprising such compds., and methods of using such compds. for inhibiting **NAALADase** enzyme activity, detecting diseases where **NAALADase** levels are altered, effecting neuronal activity, effecting TGF-b activity, inhibiting angiogenesis, and treating glutamate abnormalities, diabetic neuropathy, pain, compulsive disorders, prostate diseases, cancers and **glaucoma**. Thus, rats treated with **NAALADase** inhibitor 3-carboxy-5-(1,1-dimethylethyl)-alpha-(3-mercaptopropyl)**benzenepropanoic** acid of this invention at various dose levels (10, 1, 0.1 mg/kg) for 15 days after sciatic nerve ligation showed normalized difference in scores between the operated and unoperated paws compared to continued hyperalgesic for rats treated with vehicle under the same conditions.

ST **benzene** deriv thiol carboxylic acid drug **NAALADase** inhibitor prepn

IT Diagnosis
(agents; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Nervous system
(amyotrophic lateral sclerosis; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Nerve, disease
(demyelination; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Nerve, disease
(diabetic neuropathy; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Prostate gland
(disease; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Fertility
(disorder; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Brain, disease
(injury; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Nerve, disease
(peripheral neuropathy; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Anxiety
Blood vessel, disease
Drug delivery systems
Drugs
Enantiomers
Glaucoma (disease)
Inflammation
Medical goods
Pain
Parkinson's disease
Respiratory distress syndrome
Schizophrenia
(prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Brain, disease
(stroke; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT Spinal cord
(treatment of damage to; prepn. and uses of thiol-based **NAALADase** inhibitors)

IT 220464-68-6P, Methyl 3-bromomethyl-4-chlorobenzoate 377731-27-6P 377731-29-8P 377731-30-1P 377731-31-2P 377731-32-3P 443919-47-9P 443919-48-0P 443919-49-1P
RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(in prepn. and uses of thiol-based **NAALADase** inhibitors)

IT 1003-42-5 16308-65-9, Dimethyl 5-tert-butylisophthalate 19438-10-9,

Methyl 3-hydroxybenzoate 50995-48-7, Methyl 2,5-dibromopentanoate
91367-05-4 254737-40-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(in prepn. and uses of thiol-based **NAALADase** inhibitors)

IT 128-08-5, N-Bromosuccinimide 558-13-4, Carbon tetrabromide 13292-87-0
RL: RGT (Reagent); RACT (Reactant or reagent)
(in prepn. and uses of thiol-based **NAALADase** inhibitors)

IT **377731-26-5P 377731-28-7P** 378242-18-3P 378242-19-4P
378242-20-7P 378242-21-8P **378242-22-9P 378242-23-0P**
378242-24-1P 378242-25-2P **378242-26-3P 378242-27-4P**
378242-28-5P 378242-29-6P **378242-30-9P** 378242-31-0P
378242-32-1P 378242-35-4P 378242-36-5P 378242-37-6P 378242-38-7P
378242-39-8P 378242-40-1P 378242-41-2P 378242-43-4P
378242-44-5P 378242-45-6P **378242-46-7P**
378242-47-8P 378242-48-9P 378242-49-0P
378242-50-3P 378242-51-4P 378242-52-5P
378242-53-6P 378242-54-7P **378242-55-8P**
378242-56-9P 378242-57-0P 378242-60-5P 378242-61-6P
378242-62-7P 378242-63-8P **378242-64-9P**
378242-66-1P 378243-64-2P 378243-65-3P
378243-66-4P 378243-67-5P 378243-68-6P
378243-70-0P 378243-71-1P 378243-72-2P
378243-73-3P 378243-75-5P 378243-76-6P
378243-77-7P 378243-78-8P 378243-79-9P
378243-80-2P 378243-81-3P 443919-36-6P 443919-37-7P
443919-38-8P 443919-39-9P **443919-40-2P**
443919-41-3P 443919-42-4P 443919-43-5P
443919-44-6P 443919-45-7P 443919-46-8P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and uses of thiol-based **NAALADase** inhibitors)

IT 57-27-2, Morphine, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(prepn. and uses of thiol-based **NAALADase** inhibitors contg.)

IT 173039-10-6 200698-26-6 254737-18-3 254737-29-6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(uses of thiol-based **NAALADase** inhibitors)

IT **377731-26-5P 377731-28-7P 378242-22-9P**
378242-23-0P 378242-26-3P 378242-27-4P
378242-30-9P 378242-44-5P 378242-46-7P
378242-47-8P 378242-48-9P 378242-49-0P
378242-50-3P 378242-51-4P 378242-52-5P
378242-53-6P 378242-55-8P 378242-56-9P
378242-62-7P 378242-64-9P 378242-66-1P
378243-64-2P 378243-65-3P 378243-66-4P
378243-67-5P 378243-68-6P 378243-70-0P
378243-71-1P 378243-72-2P 378243-73-3P
378243-75-5P 378243-76-6P 378243-77-7P
378243-78-8P 378243-80-2P 378243-81-3P
443919-38-8P 443919-40-2P 443919-41-3P
443919-42-4P 443919-44-6P 443919-45-7P
443919-46-8P
RL: IMF (Industrial manufacture); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and uses of thiol-based **NAALADase** inhibitors)

RN 377731-26-5 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-2-chloro-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 377731-28-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-22-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-23-0 HCAPLUS
CN Benzenepropanoic acid, 4-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-26-3 HCAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-(2-carboxy-5-mercaptopentyl)- (9CI) (CA INDEX NAME)



RN 378242-27-4 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-4-fluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-30-9 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-44-5 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-methoxy- (9CI) (CA INDEX NAME)



RN 378242-46-7 HCAPLUS
CN Benzoic acid, 2-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-47-8 HCAPLUS
CN Benzoic acid, 4-(1-carboxy-4-mercaptobutoxy)- (9CI) (CA INDEX NAME)



RN 378242-48-9 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-2-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-49-0 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-4-chloro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-50-3 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-chloro- (9CI) (CA INDEX NAME)



RN 378242-51-4 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-4-fluoro- (9CI) (CA INDEX NAME)



RN 378242-52-5 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-2-fluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-53-6 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)-2-methoxy- (9CI) (CA INDEX NAME)



RN 378242-55-8 HCAPLUS
CN Benzenepropanoic acid, 2-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-56-9 HCAPLUS
CN Benzenepropanoic acid, 4-carboxy-2,3,5,6-tetrafluoro-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378242-62-7 HCAPLUS
CN Benzenepropanoic acid, 3-bromo-5-carboxy-.alpha.-(3-mercaptopropyl)- (9CI)
(CA INDEX NAME)



RN 378242-64-9 HCAPLUS
CN Benzenepropanoic acid, 3-bromo-4-carboxy-.alpha.-(3-mercaptopropyl)- (9CI)
(CA INDEX NAME)



RN 378242-66-1 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-nitro- (9CI)
(CA INDEX NAME)



RN 378243-64-2 HCAPLUS
CN Benzenepropanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)-2-nitro- (9CI)
(CA INDEX NAME)



RN 378243-65-3 HCAPLUS
CN [1,1'-Biphenyl]-3-propanoic acid, 3'-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-66-4 HCAPLUS
CN Benzenepropanoic acid, 2-bromo-5-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-67-5 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 378243-68-6 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



RN 378243-70-0 HCAPLUS
CN [1,1'-Biphenyl]-2-propanoic acid, 6-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-71-1 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 2-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-72-2 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-methoxy-
(9CI) (CA INDEX NAME)



RN 378243-73-3 HCAPLUS
CN [1,1'-Biphenyl]-3-propanoic acid, 2'-carboxy-.alpha.-(3-mercaptopropyl)-
(9CI) (CA INDEX NAME)



RN 378243-75-5 HCAPLUS
CN Benzenepropanoic acid, 3-(2-carboxyphenoxy)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-76-6 HCAPLUS
CN Benzenepropanoic acid, 4-(2-carboxyphenoxy)-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-77-7 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptobutyl)- (9CI) (CA INDEX NAME)



RN 378243-78-8 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 2'-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 378243-80-2 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-phenoxy- (9CI) (CA INDEX NAME)



RN 378243-81-3 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-5-(1,1-dimethylethyl)-.alpha.-(3-mercaptobutyl)- (9CI) (CA INDEX NAME)



RN 443919-38-8 HCAPLUS
CN Benzoic acid, 4-[(1-carboxy-4-mercaptobutyl)thio]- (9CI) (CA INDEX NAME)



RN 443919-40-2 HCAPLUS
CN [1,1'-Biphenyl]-3-propanoic acid, 5-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 443919-41-3 HCAPLUS
CN [1,1'-Biphenyl]-2-propanoic acid, 4-carboxy-.alpha.-(3-mercaptopropyl)- (9CI) (CA INDEX NAME)



RN 443919-42-4 HCAPLUS
CN Benzenepropanoic acid, 3-carboxy-.alpha.-(3-mercaptopropyl)-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 443919-44-6 HCAPLUS
CN Benzoic acid, 3-(1-carboxy-4-mercaptobutoxy)-5-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 443919-45-7 HCAPLUS
CN Benzoic acid, 3-[(1-carboxy-4-mercaptobutyl)thio]-5-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 443919-46-8 HCAPLUS
CN Benzoic acid, 3-[(1-carboxy-4-mercaptobutyl)amino]-5-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L103 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:353239 HCAPLUS
DN 136:374827
TI Receptor antagonist-lipid conjugates and delivery vehicles containing same
IN Ellens, Harma M.; Monck, Myrna A.; Yeh, Ping-Yang
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 28
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002036073	A2	20020510	WO 2001-US46206	20011029
	WO 2002036073	A3	20021205		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002025878	A5	20020515	AU 2002-25878	20011029
PRAI	US 2000-245140P	P	20001102		
	WO 2001-US46206	W	20011029		

OS MARPAT 136:374827
AB Vesicular drug delivery vehicles, such as liposomes, comprise a targeting ligand which comprises a non-biol., biomimetic antagonist to a receptor that is upregulated at a disease site, directly or indirectly chem. linked to a polar head group of a vesicle-forming lipid. The non-biol., biomimetic antagonist is an antagonist to a receptor upregulated in the vascular endothelium of inflammation, infection or tumor sites, selected from integrin receptors, **prostate specific membrane antigen** (PSMA) receptor, herceptin, Tie 1 and Tie 2 receptors, ICAM1, folate receptor, bFGF receptor, EGF receptor, VEGF receptor, PDGF receptor, etc. The vesicle-forming lipid is selected from phospholipids, sterols, glycolipids, cationic lipids, sphingolipids, glycerolipids, hydrophilic polymer derivs. of these lipids, gemini surfactants, etc. For example, liposomes were prepd. contg. lipid conjugates with a vitronectin receptor antagonist, (S)-7-[[N--(4-aminobutyl)-N-(benzimidazol-2-yl-methyl)]amino]carbonyl-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-**benzodiazepine**-2-acetic acid (prepn. given) 0.5 mol%, DSPC 54.5 mol%, and cholesterol 45 mol%. The liposomes were loaded with topotecan using ion gradient or polymer gradient loading/retaining techniques and administered to a patient diagnosed with ovarian cancer to inhibit growth of the cancerous tumor. A dosing regimen

was 1.5 mg/m2 of the topotecan liposomes given as a 30 min infusion over the course of 1-3 days in a week for 2 wk in a 21 day cycle, repeated for 4 cycles.

ST liposome receptor antagonist lipid conjugate targeting; inflammation infection tumor targeting receptor antagonist

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E-selectin, antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Cell adhesion molecules
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(ICAM-1 (intercellular adhesion mol. 1), antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Tyrosine kinase receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Tie, 1 and 2, antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Sialic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(analogs; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists, lipid conjugates; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Endoglins
Epidermal growth factor receptors
Laminin receptors
Platelet-derived growth factor receptors
Vascular endothelial growth factor receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cationic; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates, with receptor antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Imaging agents
(contrast; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT **Eye, disease**
(**diabetic retinopathy**; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Blood vessel
(endothelium, receptors upregulated in; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(folate, antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Surfactants
(gemini; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Lipids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(glycerolipids; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Blood vessel, neoplasm
(hemangioma, inhibitors; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Antitumor agents
(hemangioma; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Ovary, neoplasm
(inhibitors; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Drug delivery systems
(liposomes; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Antitumor agents
(ovary; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Sialic acids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polymers; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein, P-selectin, antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Anti-infective agents
Anti-inflammatory agents
Antiarthritics
Antidiabetic agents
Antirheumatic agents
Antitumor agents
Drug delivery systems
Human
Psoriasis
(receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Glycolipids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Phosphatidylserines
Phospholipids, biological studies
Polyoxyalkylenes, biological studies
Sphingolipids
Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Infection
Inflammation
Neoplasm
(receptors upregulated in vascular endothelium of; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Prostate-specific antigen
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(receptors, antagonists; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Artery, disease
(restenosis; receptor antagonist-lipid conjugates and delivery vehicles contg. same)

IT Phosphatidylcholines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, hydrogenated; receptor antagonist-lipid conjugates and delivery vehicles contg. same)